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 Quantitative phenotypes regulated by multiple genes are prevalent in nature and 
many diseases falls into this category. High-throughput sequencing and high-performance 
computing provides a basis to understand quantitative phenotypes. However, finding a statistical 
approach correctly model the phenotypes remain a challenging problem. In this work, I present a 
resampling-based approach to obtain biological functional categories from gene set and apply the 
approach to analyze lithium-sensitivity of neurological diseases and cancer. Then, the non-
parametrical permutation-based approach is applied to evaluate the performance of a GWAS 
modeling procedure. While the procedure performs well in statistics, search space reduction is 
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CHAPTER 1: Introduction - Massive Genomic Data, Database, and Analysis 
Continuous Phenotypes 
A central problem for biologists is devising how to summarize complex phenomena using 
a concise set of descriptors, when in fact many biological characteristics are not categorical at the 
phenome level of description. For example, height1, BMI2, and crop nutrient production3, are all 
"quantitative phenotypes", to name a few. While these phenotypes do have genomic basis and 
some finite heritability, but they are more complex than strictly Mendelian traits. Many widely-
studied phenotypes, including detrimental diseases4 such as schizophrenia5 and autism6, are also 
considered to be quantitative, with both genetic and environmental components contributing to 
observed phenotypic variability. Some examples of these environmental components include soil 
quality for crop harvest index7, nutrition for obesity8, and nurturing environment for intelligence9. 
A central theme of this thesis is the proper statistical methods and their implementation to 
understand biological phenomena in the context of the above descriptors. 
One century ago, Fisher proposed an “infinitesimal model” which successfully described 
genetic effects on quantitative phenotypes10. In this model, trait values are composed of a large 
number of heritable factors with small contributions in an additive way. This model was later 
developed to incorporate other factors such as recombination, selection, migration, drifting, 
mutation, and epistasis11. The model explains why heritability in continuous trait is partially 
"missing". Large number of common SNPs with statistically insignificant individual contributions 
collectively bring a compelling effect12. Therefore, exploration of continuous phenotypes calls for 
large-scale studies that require huge amount of sequencing, expression, and interaction data. 
Biologically, the "infinitesimal model" is supported by expression data and regulation network 
analysis, which find genetic regulation network to be essential in phenotype emergence13.  
  
Technology Advancement in Data Acquisition, Annotation, and Processing 
In the paper "Big Data, Astronomical or Genomical?"14, Stephens, et. al. compared the 
amount of genomic data available to-date to that of Astronomical data, YouTube and Twitter, and 
reviewed the unique challenges in genomic data acquisition, storage, distribution, and analysis. 
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The distribution stage is more related to hardware architecture and ethical issues, while the 
acquisition, storage, and analysis stages motivated developments in sequencing technologies, and 
computational tools and databases. 
Technological advancement in Next Generation Sequencing enables efficient, low-cost 
sequencing, so that enormous amount of data impossible using traditional Sanger method can be 
produced. For example, a popular sequencing technique is Illumina15. Illumina applied bridge PCR 
to amplify sequence fragments on a solid surface instead of flowing in a homogenized liquid, so 
that multiple fragments can be amplified at the same time15. Fluorescent-tagged nucleotides are 
attached to the end of fragments, one at a time, during the process of amplification. The fluorescent 
signal indicates which nucleotide is attached to the amplified fragment at each round, sequencing 
cooperatively with amplification. Raw sequence data deposited in the Sequence Read Archive 
(SRA) rapidly increases with the aid of advanced sequencing technologies.16   
Meanwhile, algorithms and large-scale computing resources have been developed to 
assemble and align the fragments sequenced. Burrows-wheeler transform17 indexes all the 
rotations of a long string. Then the rotated strings are arranged in a binary tree to enable fast search 
of substrings for alignment. De Bruijn graph organizes overlapped fragments in a directed graph 
and quickly finds combined sequence, enabling de novo assembly18. The genomic data types are 
largely heterogeneous. Tools addressing different problems have been developed and organized 
onto platforms and packages. Galaxy19 provides an online platform mainly focused on sequencing 
alignment and assembly with simple text manipulation and statistics. OMICtools20 is an online 
platform which categorizes online tools by evaluating literature and provides an AI-aided tool 
choice and workflow construction corresponding to the biological question of interest. For 
command-line workflows, Biopython21 provides tools for sequence parsing, alignment, motif 
prediction, annotation, and statistics. Bioconductor22 has about 1560 project-oriented tools 
deposited. Besides providing a convenient access to databases, Bioconductor, based on R 
language, is especially strong for performing statistical analysis and presenting data. 
Databases have evolved to accompany the sequencing data and annotate the genomic 
information with their biological products and function. Oxford journal website provides a 
comprehensive collection of databases for convenient search23. Database updates are annually 
reported on the Nucleic Acid Research database issue23. Sequencing annotation databases include 
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SRA for raw sequencing data and alignment16, DDBJ for nucleotide and protein sequences24, and 
GenBank integrating nucleotide sequencing with gene products, protein structure, and biomedical 
literature25. ENCODE26 project collects highly specified sequencing data in human, mouse, C. 
elegans, and fruit fly, including genome sequences, epigenetic patterns, regulatory binding sites, 
and chromatin contact information. Databases annotating genomic polymorphisms include 
dbSNP27 and dbVar28, which annotate mutations and structure variations in human chromosome, 
their frequencies, and impact on function and disease susceptibility. JASPER29 and DBTSS30 
integrate sequence information for transcription factor binding sites from various species and cell 
types based on immunoprecipitation, methylation, and RNA sequencing experiments. 
FANTOM531 provides an atlas for regulatory RNA in human and mouse, as well as promoters and 
enhancers in human. ArrayExpress32 and Gene Expression Omnibus33 archive microarray 
experiment data and make expression data set available for further regulation network study and 
functional category analysis. UniProt34 provides a hub annotating protein sequences with rich 
information including but not limited to: function, activity, active sites, binding regions, post-
translational modification, interaction, structure, mutations, and related diseases. OMA35, 
OrthoDB36 and Pfam37 organize protein by sequence and domain similarity to explore evolution 
in function. Protein-protein interaction databases such as STRING38 and BioGRID39 compile 
networks through physical contact and functional regulations. KEGG40 and GO (Gene Ontology)41 
link genes to a systems-functional level of pathways and biological knowledge. An important task 
is to integrate these data sources for use in projects that tackle biological problems with multiple 
aspects. One effort is to provide direct mapping or even a common language for cross-talk between 
databases. BioMart42 from Ensembl project43 provides a mapping among different systems of gene 
and gene product symbols and their functional attributes. Gene Ontology Consortium initially 
begun with providing a cross-species description of genetic functions41. Based on similar 
approaches, KaBOB44 system semantically integrates 18 biomedical databases and provides 
consistent representation of biomedical data and concepts.  
 
 
Permutation-based Resampling Method for Assessing Many-to-Many 
Mapping 
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Associating genomic data with phenotype is a multi-dimensional problem. When the gene-
function annotation is available, what functional categories and pathways are overrepresented our 
gene set? In this case, many ontology terms or pathways are simultaneously tested for their 
enrichment. When the gene/variant-function annotation is unavailable, what would be a proper 
model describing the system? In this case, multiple models are tested.  
When multiple hypotheses are tested, one might find more false positives than suggested 
by an uncorrected p-value with a fixed threshold. For example, when we evaluated m0 null 
hypotheses and found m rejected with a threshold , then the probability to have at least one false 
positive would be approximately m0. Bonferroni correction is a stringent threshold so that the 
possibility to mistakenly reject 1 true null-hypothesis is under . While it is too stringent for gene 
ontology analysis, it is still widely used in genetic variant association studies due to its simplicity. 
Benjamini-Hochberg correction controls false discovery rate (FDR) under  assuming 
independent or positively-correlated hypotheses45. The Benjamini-Yekutieli method extends 
corrections to negatively correlated hypotheses46. A recent modification of the Benjamini-
Hochberg method aims to account for acyclic tree-like structures47. 
These methods are very useful, but none provide a completely reliable estimation of false 
positives, due to the extremely interconnected nature of the elements in gene ontology, other 
biological databases, and genomic models. The assumption of independency or positive-
correlation is not always valid. Therefore, non-parametric simulated statistics, is essential for 
accurate assessment of the significance of correlations. Chapters 1-3 discusses that when 
association is known, genes are permuted with background gene list to show how many annotation 
terms are overrepresented by chance. Chapter 4 would present the case when association is 
unknown, permuting phenotypes would show what associations occurs by chance and therefore 
sets a threshold to control False Positive Rate. 
Improving Statistics of Gene Set Analysis, and overview of Thesis Chapter 1 
Understanding biology in terms of categories generally reduces to a set of binary 
classification problems.  For each potential category that might describe a system, the question is: 
“Does that category fit?”  Next, since the data are stochastic by nature, we also ask: “How 
confident are we that this category fits?” and “Is it more important to find as many relevant 
categories as possible, or to be very sure that the identified categories are correct?” Chapter 1 of 
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the thesis deals with these questions as they apply to gene annotation enrichment studies, in which 
a list of genes is analyzed for enrichment in a number of biological process-related categories, thus 
pinpointing which biological processes these genes enable. 
The most straightforward way to quickly obtain an overview of biological information in 
a large data set is to evaluate whether a biological feature is overrepresented in the gene set.  
Huang, et.al. (2008)48 reviewed the gene ontology enrichment tools available at the time and 
categorized them into singular enrichment analysis (SEA), gene set enrichment analysis (GSEA), 
and modular enrichment analysis (MEA). SEA uses hypergeometric test, Fisher's exact test, or 
Chi-squared test to evaluate whether the fraction of the genes associated with a certain biological 
feature in the gene set of interest is reached or exceeded by chance contrasting a background gene 
set48. GSEA applies permutations between experiment and control gene sets to find distribution of 
maximum enrichment score and its significance48. MEA incorporates network relationships 
between annotated terms with SEA48. In the present thesis, a pipeline improving SEA with a 
GSEA-like random-sampling like procedure is developed, so that the permutation procedures 
would also be applicable even if gene rank metric or case-control format are hard to obtain. 
MEA tools try to overcome the disadvantage of multiple hypothesis correction of SEA by 
including the acyclic tree structure. TopGO options "elim"49 and "parent-child"50 adjust the 
candidate gene association with a parent term if a child term is found to be enriched. DAVID51 
provides a hierarchical enrichment option so that the terms at the same level would be evaluated 
at the same time. However, the hierarchical enrichment overlooks the fact that a child term can 
have multiple parents across levels and the levels of gene ontology terms themselves are poorly 
defines. Moreover, MEA tools overlook the overlap between the sibling terms, cousin terms, and 
distant terms due to genetic pleiotropy. For these terms, selection of an overlapped gene would 
bring positive correlation, while selection of a non-overlapped gene would bring negative 
correlation. Therefore, we choose to combine SEA tools with resampling method.  
In chapter one, a resampling-based method is introduced for false positive rate control. 
"Null sets", the gene sets randomly selected from background gene set, are evaluated as an 
estimation for false positives.  
Another aspect discussed in chapter one is inclusion of false negatives, which is motivated 
by application of gene ontology enrichment in our data set of interest, the human orthologs of 
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honey bee alarm pheromone set. The honey bee alarm pheromone set is a set of genes differentially 
expressed when honey bee aggression behavior is triggered by the chemical alarm pheromone52. 
This honey bee gene set is shown to be more conserved with social placental mammals such as 
human, than non-social insects53. It is likely to provide understanding to genetic basis to social 
behavior. However, using both heuristic and resampling method with FDR<=0.05 brings only the 
most general gene ontology terms. The false negative is investigated. Metrics54,55 , such as F-
measure and Matthews Correlation Coefficient, balancing false negatives and true positives are 
introduced. Optimizing these metrics provides a statistical basis to rationally alter p-value 
thresholds. Relaxing significance threshold to balance signal and noise may bring back more 
specific gene ontology terms, than an arbitrary threshold. 
The biological basis of complex continuous phenotypes also justifies increasing thresholds 
to embrace the previously thought “insignificant” terms. Complex continuous phenotypes are 
regulated by large quantity of genes with small contributions cooperating in a non-centralized 
network. The small alarm-pheromone set human ortholog is not contradicting to the feature in that 
a non-centralized network still maintains its general properties even if a certain portion of 
nodes/genes is removed. On the other hand, contributions of “insignificant” ontology terms would 
be large due to the large population of these terms. Therefore, it is also biologically reasonable to 
relax the threshold if optimization of balancing metrics requires.  
Application of Simulated Enrichment Statistics on Lithium Sensitive Gene 
Sets, and overview of Thesis chapters 2 and 3 
Chapters two and three apply statistical method from chapter one for a systems analysis of 
lithium-sensitive genes. Jakobsson, et.al. have provided a comprehensive review of the 
biochemical mechanism of lithium function and its importance in neurodegenerative disease, 
affective disorder, and cancer56. Lithium has been used as a treatment in major depressive 
disorder57, bipolar disorder58, and schizophrenia59. In combined treatment, lithium has enhanced 
effects of SSRI60. Epidemiology studies have revealed that lithium concentration negatively 
correlate with dementia61 and rising rates of Alzheimer's disease mortality with age62. 
Retrospective studies have revealed that lithium reduced cancer risk in patients with bipolar 
disorder63. Li+ competes with Mg2+ in binding with many kinases including GSK3B64, which 
regulates a large number of substrates65. Among the substrates inhibited by GSK3B, BDNF66 has 
shown neuro-protective function and has been a therapeutic target for Alzheimer's disease67. 
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Lithium inhibition of inositol monophosphatase, which is another Mg2+ binding enzyme, have 
been shown to induce autophagy68.  
To systematically study the effect of lithium, it is key to understand how the Mg2+ binding 
enzyme interactive network is involved in the disease-related biochemical pathways. The protein-
protein interaction database STRING38 provides annotations based on experiment, ortholog 
evidence, and computational prediction. The interactome largely covering same genes are merged 
together. Eventually, 10 distinctive interactomes become the input of the enrichment analysis. 
Each interactome is then processed by the pipeline developed in chapter 1 for a resampling-based 
KEGG pathway enrichment study using 1000 null sets.  
For each disease annotated in the KEGG database40, either they are annotated to a single 
disease term or to multiple pathway terms. A collective p-value is computed by the geometric 
mean of all the p-value of mutual enrichment of interactome and KEGG terms associated with the 
disease. The lower the p-value, the more sensitive the disease would be to lithium. We used the 
analysis to identify which cancers and neurological diseases are likely to be most responsive to 
lithium therapy and which genes are most promising targets in a multidrug therapy involving 
lithium.    
The calculation result has shown that except for very few outliers, cancer terms has 
achieved the lowest collective p-value. A majority of neurodegenerative disease and affective 
disorder have good enrichment in lithium interactome. Metabolic pathways are not responsive to 
lithium interactomes. The bipolar disorder and major depressive disorder, which are clinically 
proved to be sensitive to lithium treatment, have shown high enrichment. 
The key genes are evaluated by how many times they appeared in the intersection of a 
disease-related pathway and lithium interactome. The number is normalized by the number of 
pathways associated with the disease. Among the highly ranked genes, many are known to be the 
drug target for disease treatment. For example, the APP is identified as a key protein in 
Alzheimer’s disease and major depressive disorder. In both diseases, amyloid-beta produced by 
abnormal cleavage of APP are observed clinically69,70. MAPK3, associated with cell apoptosis71,  
is both highly ranked in neurodegenerative disorder and cancer. 
The study is limited with direct annotation and the contribution of individual genes are 
assumed to be the same, which is not the case in reality. However, it is a quick way to indicate 
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which diseases are sensitive to lithium treatment, yet regardless of the direction. Many of the well-
identified drug targets, including the key enzymes themselves, are absent from the direct 
annotation. The interaction network showed how these genes regulates the highly ranked genes 
found in the study and bridges lithium effects on the diseases. 
Quantitative Model for GWAS Data and Search Space Reduction: overview 
of Chapter 4 
Gene mutation, differential expression sensitivity to environment, and interaction are 
ultimately associated with phenotype variations. Especially, mutations in non-coding region is 
expected to result in less detrimental consequences to phenotype than those in coding regions. But 
these variations would alter phenotypes by regulating the expression of genes72. Therefore, it is 
necessary to include variations in both coding and non-coding regions to build a genotype-to-
phenotype model of high resolution. It is also found that mutations interact (epistasis), resulting in 
greater effect on phenotype than would have been the sum of individual contributions, particularly 
in complex continuous phenotypes73. Therefore, to describe a continuous phenotype, a quantitative 
model including both additive and epistatic effects based on regression is necessary. 
In chapter four, a Stepwise Procedure for constructing an Additive and Epistatic Multi-
Locus model (SPAEML) is described. This model includes both first order (additive) and second 
order (two-way epistatic) terms and a normal random noise term74. The model is fitted by step-
wise model selection procedure75. To evaluate the effectiveness of the model, it is compared to 
two other statistical approaches. One is Joint Linkage analysis76, which is a multi-locus model that 
does not incorporate epistasis. The other is FastEpistasis77, which only includes one pair of 
epistatic markers in each model. 
The applications were tested on synthetic data sets and validated by linear fitting using R. 
False positive rate, detection rate, and specification rate are evaluated. It is confirmed that the 
multi-locus models (SPAEML and JL) outperforms single-locus model. The SPAEML is able to 
specify epistatic and additive effect when minor allele frequency is high. However, due to 
combinatorial growth of number of models to test, SPAEML takes much longer time to run than 
JL (a week vs three hours). Therefore, search space reduction is necessary.  
Future work: Search Space Reduction in Model Selection  
 9 
Currently, many efforts have been taken to reduce the possible search space. Pure statistical 
methods are quickly developed. For example, LASSO78 captures the strongest effect by adding 
constraint term in regression procedure. "Screen and Clean"79 showed a two-staged workflow 
finding all the additive effects with LASSO and then only fit the interactive pairs between the 
SNPs identified.  In addition to statistical methods, it would also be helpful to take advantage of 
the prior biological knowledge to effectively exclude the models that are not biologically 
meaningful. MDR80 categorized multi-locus data into high-risk and low-risk group so that the 
combination of multiple factors is reduced to two groups. Later versions of MDR also work with 
quantitative phenotypes.81 
Haplotyping is one such approach. Experiments have shown that human chromosomes are 
organized in haplotype blocks where the groups of genomic variations82 are likely to be inherited 
together. Therefore, grouping SNPs in haplotype blocks would effectively reduce the candidate 
markers in the model83,84,85.  
Additionally, the molecular basis of epistasis lies in gene regulation network86. Magnum87 
builds on about 200 tissue-specific regulatory network information from FANTOM531and 
validated by GTEx88. KnowENG89 incorporates the interaction information from databases like 
STRING38, annotation databases like KEGG40 and GO41, and protein domain similarity 
information to predict interaction between exons. Juicer tool packages90 process Hi-C data to 
reveal 3D structure of chromatin and bring information about contact probability of long-distance 
genetic elements. These software packages enable evaluation of interaction probability and 
provide effective ways to integrate regulatory and co-expression information in modeling. 
Stochastic search and non-parametrical model building approaches have been extensively 
developed for effectively build a model for GWAS data. Ljungberg, et.al. (2004)91 provided an 
efficient algorithm by hierarchically and stochastically partitioning the search space to find global 
optimal in 2 and 3 QTN models with many-way interactions. Wan, et.al. (2009)92 developed a 
machine-learning tree search algorithm to identify interactive SNPs. However, there are no unified 
workflow that can take the genotype and phenotype table and automatically reduce search space, 
select SNP and SNP pairs, and fit for the model. My next goal is to explore these algorithms and 
incorporate statistical structure in the given genomic data set and priori biological knowledge, so 
 10 
that a straightforward workflow can be developed for accurately description of continuous 
phenotype using multi-locus, interaction-inclusive models.  
Conclusion 
In this work, I have demonstrated that non-parametrical statistics is now a feasible way to 
analyze genomic data. For gene annotation enrichment analysis, resampling simulation estimates 
false discovery rate in an unbiased way regardless the structure of the database. A flexible 
significance threshold balancing detection and correctness is better than an arbitrary threshold in 
exploring highly noised data set such as the honey bee alarm pheromone set. Application the 
resampling approach for mutual enrichment in lithium-sensitive gene set and disease-associated 
pathways is a fast and straightforward way to identify disease responsive to lithium and potential 
pharmaceutical targets for these diseases. In GWAS analysis where data set is much larger, 
permutation method is more computationally challenging. For a small data set, I was able to 
validate the step-wise procedure including both additive and epistatic effects for multi-locus model 
(SPAEML). The performance for the modeling procedure was evaluated using permutation 
method and simulated data set. For realistic-sized data set, search-space-reduction for potential 
model is essential. 
1 Jelenkovic, A., Sund, R., Hur, Y. M., Yokoyama, Y., Hjelmborg, J. V. B., Möller, S., ... & Aaltonen, S. (2016). Genetic and environmental 
influences on height from infancy to early adulthood: An individual-based pooled analysis of 45 twin cohorts. Scientific reports, 6, 28496. 
2 Locke, A. E., Kahali, B., Berndt, S. I., Justice, A. E., Pers, T. H., Day, F. R., ... & Croteau-Chonka, D. C. (2015). Genetic studies of body mass 
index yield new insights for obesity biology. Nature, 518(7538), 197. 
3 Owens, B. F., Lipka, A. E., Magallanes-Lundback, M., Tiede, T., Diepenbrock, C. H., Kandianis, C. B., ... & Buckler, E. S. (2014). A foundation 
for provitamin A biofortification of maize: genome-wide association and genomic prediction models of carotenoid levels. Genetics, 198(4), 1699-
1716. 
4 McCarthy, Mark I., et al. "Genome-wide association studies for complex traits: consensus, uncertainty and challenges." Nature reviews 
genetics 9.5 (2008): 356. 
5 Sullivan, Patrick F., Kenneth S. Kendler, and Michael C. Neale. "Schizophrenia as a complex trait: evidence from a meta-analysis of twin 
studies." Archives of general psychiatry60.12 (2003): 1187-1192. 
6 Hallmayer, J., Cleveland, S., Torres, A., Phillips, J., Cohen, B., Torigoe, T., ... & Lotspeich, L. (2011). Genetic heritability and shared 
environmental factors among twin pairs with autism. Archives of general psychiatry, 68(11), 1095-1102. 
7 Cassman, K. G. (1999). Ecological intensification of cereal production systems: yield potential, soil quality, and precision agriculture. Proceedings 
of the National Academy of Sciences, 96(11), 5952-5959. 
8 Speakman, J. R. (2004). Obesity: the integrated roles of environment and genetics. The Journal of nutrition, 134(8), 2090S-2105S. 
9 Davies, G., Tenesa, A., Payton, A., Yang, J., Harris, S. E., Liewald, D., ... & McGhee, K. (2011). Genome-wide association studies establish that 
human intelligence is highly heritable and polygenic. Molecular psychiatry, 16(10), 996. 
10 R.A. Fisher. "The correlation between relatives on the supposition of Mendelian inheritance." 
                                                 
 11 
                                                                                                                                                             
Trans. R. Soc. Edinb., 52 (1918), pp. 399-433 
11 Barton, Nick H., Alison M. Etheridge, and Amandine Véber. "The infinitesimal model." bioRxiv (2016): 039768. 
12 Yang, J., Benyamin, B., McEvoy, B. P., Gordon, S., Henders, A. K., Nyholt, D. R., ... & Goddard, M. E. (2010). Common SNPs explain a large 
proportion of the heritability for human height. Nature genetics, 42(7), 565. 
13 Boyle, Evan A., Yang I. Li, and Jonathan K. Pritchard. "An expanded view of complex traits: from polygenic to omnigenic." Cell 169.7 (2017): 
1177-1186. 
14 Stephens, Z. D., Lee, S. Y., Faghri, F., Campbell, R. H., Zhai, C., Efron, M. J., ... & Robinson, G. E. (2015). Big data: astronomical or 
genomical? PLoS biology, 13(7), e1002195. 
15 "Illumina Sequencing Technology Highest data accuracy, simple workflow, and a broad range of applications." [pdf file] 
https://www.illumina.com/documents/products/techspotlights/techspotlight_sequencing.pdf 
16 Kodama, Y., Shumway, M., & Leinonen, R. (2011). The Sequence Read Archive: explosive growth of sequencing data. Nucleic acids 
research, 40(D1), D54-D56. 
17 Li, H., & Durbin, R. (2009). Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics, 25(14), 1754-1760. 
18 Zerbino, D. R., & Birney, E. (2008). Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome research, 18(5), 821-
829. 
19 Afgan, E., Baker, D., Van den Beek, M., Blankenberg, D., Bouvier, D., Čech, M., ... & Grüning, B. (2016). The Galaxy platform for accessible, 
reproducible and collaborative biomedical analyses: 2016 update. Nucleic acids research, 44(W1), W3-W10. 
20 Henry, V. J., Bandrowski, A. E., Pepin, A. S., Gonzalez, B. J., & Desfeux, A. (2014). OMICtools: an informative directory for multi-omic data 
analysis. Database, 2014. 
21 Cock, P. J., Antao, T., Chang, J. T., Chapman, B. A., Cox, C. J., Dalke, A., ... & De Hoon, M. J. (2009). Biopython: freely available Python 
tools for computational molecular biology and bioinformatics. Bioinformatics, 25(11), 1422-1423. 
22 Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., ... & Hornik, K. (2004). Bioconductor: open software 
development for computational biology and bioinformatics. Genome biology, 5(10), R80. 
23 Galperin, M. Y., Fernández-Suárez, X. M., & Rigden, D. J. (2017). The 24th annual Nucleic Acids Research database issue: a look back and 
upcoming changes. Nucleic acids research, 45(D1), D1-D11. 
24 Kodama, Y., Mashima, J., Kosuge, T., Katayama, T., Fujisawa, T., Kaminuma, E., ... & Nakamura, Y. (2014). The DDBJ Japanese Genotype-
phenotype Archive for genetic and phenotypic human data. Nucleic acids research, 43(D1), D18-D22. 
25 Benson, D. A., Cavanaugh, M., Clark, K., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J., & Sayers, E. W. (2012). GenBank. Nucleic acids 
research, 41(D1), D36-D42. 
26 ENCODE Project Consortium. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature, 489(7414), 57. 
27 Sherry, S. T., Ward, M. H., Kholodov, M., Baker, J., Phan, L., Smigielski, E. M., & Sirotkin, K. (2001). dbSNP: the NCBI database of genetic 
variation. Nucleic acids research, 29(1), 308-311. 
28 Lappalainen, I., Lopez, J., Skipper, L., Hefferon, T., Spalding, J. D., Garner, J., ... & Paschall, J. (2012). DbVar and DGVa: public archives for 
genomic structural variation. Nucleic acids research, 41(D1), D936-D941. 
29 Mathelier, A., Zhao, X., Zhang, A. W., Parcy, F., Worsley-Hunt, R., Arenillas, D. J., ... & Lim, J. (2013). JASPAR 2014: an extensively expanded 
and updated open-access database of transcription factor binding profiles. Nucleic acids research, 42(D1), D142-D147. 
30 Suzuki, A., Wakaguri, H., Yamashita, R., Kawano, S., Tsuchihara, K., Sugano, S., ... & Nakai, K. (2014). DBTSS as an integrative platform for 
transcriptome, epigenome and genome sequence variation data. Nucleic acids research, 43(D1), D87-D91. 
31 Cunningham, F., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., ... & Gil, L. (2014). Ensembl 2015. Nucleic acids research, 43(D1), 
D662-D669. 
32 Parkinson, H., Kapushesky, M., Shojatalab, M., Abeygunawardena, N., Coulson, R., Farne, A., ... & Mani, R. (2006). ArrayExpress—a public 
database of microarray experiments and gene expression profiles. Nucleic acids research, 35(suppl_1), D747-D750. 
33 Edgar, R., Domrachev, M., & Lash, A. E. (2002). Gene Expression Omnibus: NCBI gene expression and hybridization array data 
repository. Nucleic acids research, 30(1), 207-210. 
34 UniProt Consortium. (2014). UniProt: a hub for protein information. Nucleic acids research, 43(D1), D204-D212. 
 12 
                                                                                                                                                             
35 Altenhoff, A. M., Škunca, N., Glover, N., Train, C. M., Sueki, A., Piližota, I., ... & Gonnet, G. H. (2014). The OMA orthology database in 2015: 
function predictions, better plant support, synteny view and other improvements. Nucleic acids research, 43(D1), D240-D249. 
36 Zdobnov, E. M., Tegenfeldt, F., Kuznetsov, D., Waterhouse, R. M., Simao, F. A., Ioannidis, P., ... & Kriventseva, E. V. (2016). OrthoDB v9. 1: 
cataloging evolutionary and functional annotations for animal, fungal, plant, archaeal, bacterial and viral orthologs. Nucleic acids research, 45(D1), 
D744-D749. 
37 Finn, R. D., Bateman, A., Clements, J., Coggill, P., Eberhardt, R. Y., Eddy, S. R., ... & Sonnhammer, E. L. (2013). Pfam: the protein families 
database. Nucleic acids research, 42(D1), D222-D230. 
38 Szklarczyk, D., Franceschini, A., Wyder, S., Forslund, K., Heller, D., Huerta-Cepas, J., ... & Kuhn, M. (2014). STRING v10: protein–protein 
interaction networks, integrated over the tree of life. Nucleic acids research, 43(D1), D447-D452. 
39 Stark, C., Breitkreutz, B. J., Reguly, T., Boucher, L., Breitkreutz, A., & Tyers, M. (2006). BioGRID: a general repository for interaction 
datasets. Nucleic acids research, 34(suppl_1), D535-D539. 
40 Kanehisa, M., & Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic acids research, 28(1), 27-30. 
41 Gene Ontology Consortium. (2014). Gene ontology consortium: going forward. Nucleic acids research, 43(D1), D1049-D1056. 
42 Kasprzyk, A. (2011). BioMart: driving a paradigm change in biological data management. Database, 2011. 
43 Hubbard, T., Barker, D., Birney, E., Cameron, G., Chen, Y., Clark, L., ... & Durbin, R. (2002). The Ensembl genome database project. Nucleic 
acids research, 30(1), 38-41. 
44 Livingston, K. M., Bada, M., Baumgartner, W. A., & Hunter, L. E. (2015). KaBOB: ontology-based semantic integration of biomedical 
databases. BMC bioinformatics, 16(1), 126. 
45 Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of 
the royal statistical society. Series B (Methodological), 289-300. 
46 Benjamini, Y., & Yekutieli, D. (2001). The control of the false discovery rate in multiple testing under dependency. Annals of statistics, 1165-
1188. 
47 Bogomolov, M., Peterson, C. B., Benjamini, Y., & Sabatti, C. (2017). Testing hypotheses on a tree: new error rates and controlling 
strategies. arXiv preprint arXiv:1705.07529. 
48 Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2008). Bioinformatics enrichment tools: paths toward the comprehensive functional analysis 
of large gene lists. Nucleic acids research, 37(1), 1-13. 
49 Alexa, A., Rahnenführer, J., & Lengauer, T. (2006). Improved scoring of functional groups from gene expression data by decorrelating GO 
graph structure. Bioinformatics, 22(13), 1600-1607. 
50 Goeman, J. J., & Bühlmann, P. (2007). Analyzing gene expression data in terms of gene sets: methodological issues. Bioinformatics, 23(8), 980-
987. 
51 Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2008). Systematic and integrative analysis of large gene lists using DAVID bioinformatics 
resources. Nature protocols, 4(1), 44. 
52 Alaux, C., Sinha, S., Hasadsri, L., Hunt, G. J., Guzmán-Novoa, E., DeGrandi-Hoffman, G., ... & Robinson, G. E. (2009). Honey bee aggression 
supports a link between gene regulation and behavioral evolution. Proceedings of the National Academy of Sciences, 106(36), 15400-15405. 
53 Liu, H., Robinson, G. E., & Jakobsson, E. (2016). Conservation in mammals of genes associated with aggression-related behavioral phenotypes 
in honey bees. PLoS computational biology, 12(6), e1004921. 
54 Powers, D. M. (2011). Evaluation: from precision, recall and F-measure to ROC, informedness, markedness and correlation. 
55 Matthews, B. W. (1975). Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochimica et Biophysica Acta 
(BBA)-Protein Structure, 405(2), 442-451. 
56 Jakobsson, E., Argüello-Miranda, O., Chiu, S. W., Fazal, Z., Kruczek, J., Nunez-Corrales, S., ... & Pritchet, L. (2017). Towards a Unified 
Understanding of Lithium Action in Basic Biology and its Significance for Applied Biology. The Journal of membrane biology, 250(6), 587-604. 
57 Treiser, S. L., Cascio, C. S., O'Donohue, T. L., Thoa, N. B., Jacobowitz, D. M., & Kellar, K. J. (1981). Lithium increases serotonin release and 
decreases serotonin receptors in the hippocampus. Science, 213(4515), 1529-1531. 
58 American Psychiatric Association. (2002). Practice guideline for the treatment of patients with bipolar disorder (revision). American Psychiatric 
Pub. 
 13 
                                                                                                                                                             
59 Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., ... & WFSBP Task force on Treatment Guidelines for 
Schizophrenia. (2013). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 
2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. The world journal of biological 
psychiatry, 14(1), 2-44. 
60 Crossley, N. A., & Bauer, M. (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses 
of randomized, placebo-controlled trials. The Journal of clinical psychiatry. 
61 Kessing, L. V., Gerds, T. A., Knudsen, N. N., Jørgensen, L. F., Kristiansen, S. M., Voutchkova, D., ... & Ersbøll, A. K. (2017). Association of 
lithium in drinking water with the incidence of dementia. JAMA psychiatry, 74(10), 1005-1010. 
62 Fajardo, V. A., Fajardo, V. A., LeBlanc, P. J., & MacPherson, R. E. (2018). Examining the Relationship between Trace Lithium in Drinking 
Water and the Rising Rates of Age-Adjusted Alzheimer’s Disease Mortality in Texas. Journal of Alzheimer's Disease, (Preprint), 1-10. 
63 Martinsson, L., Westman, J., Hällgren, J., Ösby, U., & Backlund, L. (2016). Lithium treatment and cancer incidence in bipolar disorder. Bipolar 
disorders, 18(1), 33-40. 
64 Ryves, W. J., & Harwood, A. J. (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochemical and 
biophysical research communications, 280(3), 720-725. 
65 Beurel, E., Grieco, S. F., & Jope, R. S. (2015). Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacology & 
therapeutics, 148, 114-131. 
66 Mai, L., Jope, R. S., & Li, X. (2002). BDNF‐mediated signal transduction is modulated by GSK3β and mood stabilizing agents. Journal of 
neurochemistry, 82(1), 75-83. 
67 Nagahara, A. H., & Tuszynski, M. H. (2011). Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature reviews 
Drug discovery, 10(3), 209. 
68 Sarkar, S., Floto, R. A., Berger, Z., Imarisio, S., Cordenier, A., Pasco, M., ... & Rubinsztein, D. C. (2005). Lithium induces autophagy by 
inhibiting inositol monophosphatase. J Cell Biol, 170(7), 1101-1111. 
69 Julia, T. C. W., & Goate, A. M. (2017). Genetics of β-amyloid precursor protein in Alzheimer's disease. Cold Spring Harbor perspectives in 
medicine, 7(6), a024539. 
70 Pomara, N., & Bruno, D. (2016). Major depression may lead to elevations in potentially neurotoxic amyloid beta species independently of 
Alzheimer Disease. The American Journal of Geriatric Psychiatry, 24(9), 773-775. 
71 Minutoli, L., Antonuccio, P., Polito, F., Bitto, A., Squadrito, F., Di Stefano, V., ... & Altavilla, D. (2009). Mitogen-activated protein kinase 
3/mitogen-activated protein kinase 1 activates apoptosis during testicular ischemia–reperfusion injury in a nuclear factor-κB-independent 
manner. European journal of pharmacology, 604(1-3), 27-35. 
72 Cubillos, F. A., Coustham, V., & Loudet, O. (2012). Lessons from eQTL mapping studies: non-coding regions and their role behind natural 
phenotypic variation in plants. Current opinion in plant biology, 15(2), 192-198. 
73 Carlborg, Ö., & Haley, C. S. (2004). Epistasis: too often neglected in complex trait studies?. Nature Reviews Genetics, 5(8), 618. 
74 Bogdan, M., Ghosh, J. K., & Doerge, R. W. (2004). Modifying the Schwarz Bayesian information criterion to locate multiple interacting 
quantitative trait loci. Genetics, 167(2), 989-999. 
75 Segura, V., Vilhjálmsson, B. J., Platt, A., Korte, A., Seren, Ü., Long, Q., & Nordborg, M. (2012). An efficient multi-locus mixed-model approach 
for genome-wide association studies in structured populations. Nature genetics, 44(7), 825. 
76 Bradbury, P. J., Zhang, Z., Kroon, D. E., Casstevens, T. M., Ramdoss, Y., & Buckler, E. S. (2007). TASSEL: software for association mapping 
of complex traits in diverse samples. Bioinformatics, 23(19), 2633-2635. 
77 Schüpbach, T., Xenarios, I., Bergmann, S., & Kapur, K. (2010). FastEpistasis: a high performance computing solution for quantitative trait 
epistasis. Bioinformatics, 26(11), 1468-1469. 
78 Tibshirani, R. (1996). Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society. Series B (Methodological), 267-
288. 
79 Wu, J., Devlin, B., Ringquist, S., Trucco, M., & Roeder, K. (2010). Screen and clean: a tool for identifying interactions in genome‐wide 
association studies. Genetic epidemiology, 34(3), 275-285. 
80 Hahn, L. W., Ritchie, M. D., & Moore, J. H. (2003). Multifactor dimensionality reduction software for detecting gene–gene and gene–
environment interactions. Bioinformatics, 19(3), 376-382. 
 14 
                                                                                                                                                             
81 Lou, X. Y., Chen, G. B., Yan, L., Ma, J. Z., Zhu, J., Elston, R. C., & Li, M. D. (2007). A generalized combinatorial approach for detecting gene-
by-gene and gene-by-environment interactions with application to nicotine dependence. The American Journal of Human Genetics, 80(6), 1125-
1137. 
82 Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., ... & Liu-Cordero, S. N. (2002). The structure of haplotype 
blocks in the human genome. Science, 296(5576), 2225-2229. 
83 Lamparter, D., Marbach, D., Rueedi, R., Kutalik, Z., & Bergmann, S. (2016). Fast and rigorous computation of gene and pathway scores from 
SNP-based summary statistics. PLoS computational biology, 12(1), e1004714. 
84 Cowman, T., & Koyutürk, M. (2017). Prioritizing tests of epistasis through hierarchical representation of genomic redundancies. Nucleic acids 
research, 45(14), e131-e131. 
85 Zhang, Y., Zhang, J., & Liu, J. S. (2011). Block-based Bayesian epistasis association mapping with application to WTCCC type 1 diabetes 
data. The annals of applied statistics, 5(3), 2052. 
86 Lehner, B. (2011). Molecular mechanisms of epistasis within and between genes. Trends in Genetics, 27(8), 323-331. 
87 Marbach, D., Lamparter, D., Quon, G., Kellis, M., Kutalik, Z., & Bergmann, S. (2016). Tissue-specific regulatory circuits reveal variable 
modular perturbations across complex diseases. Nature methods, 13(4), 366. 
88 GTEx Consortium. (2015). The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science, 348(6235), 
648-660. 
89 Sinha, S., Song, J., Weinshilboum, R., Jongeneel, V., & Han, J. (2015). KnowEnG: a knowledge engine for genomics. Journal of the American 
Medical Informatics Association, 22(6), 1115-1119. 
90 Durand, N. C., Shamim, M. S., Machol, I., Rao, S. S., Huntley, M. H., Lander, E. S., & Aiden, E. L. (2016). Juicer provides a one-click system 
for analyzing loop-resolution Hi-C experiments. Cell systems, 3(1), 95-98. 
91 Ljungberg, K., Holmgren, S., & Carlborg, Ö. (2004). Simultaneous search for multiple QTL using the global optimization algorithm 
DIRECT. Bioinformatics, 20(12), 1887-1895. 
92 Wan, X., Yang, C., Yang, Q., Xue, H., Tang, N. L., & Yu, W. (2009). Predictive rule inference for epistatic interaction detection in genome-
wide association studies. Bioinformatics, 26(1), 30-37. 
 
 15 
CHAPTER 2: Using Optimal F-measure and Random Resampling in Gene 
Ontology Enrichment Calculations 
(Submitted to Frontiers in Applied Mathematics and Statistics, in Review) 
Weihao Ge, Zeeshan Fazal and Eric Jakobsson* 
*Correspondence: jake@illinois.edu 
Abstract 
Background: A central question in bioinformatics is how to minimize arbitrariness and bias in analysis 
of patterns of enrichment in data.  A prime example of such a question is enrichment of gene ontology 
(GO) classes in lists of genes. Our paper deals with two issues within this larger question.  One is how 
to calculate the false discovery rate (FDR) within a set of apparently enriched ontologies, and the 
second how to set that FDR within the context of assessing significance for addressing biological 
questions, to answer these questions we compare a random resampling method with a commonly used 
method for assessing FDR, the Benjamini-Hochberg (BH) method. We further develop a heuristic 
method for evaluating Type II (false negative) errors to enable utilization of F-Measure binary 
classification theory for distinguishing “significant” from “non-significant” degrees of enrichment. 
Results: The results show the preferability and feasibility of random resampling assessment of FDR 
over the analytical methods with which we compare it. They also show that the reasonableness of any 
arbitrary threshold depends strongly on the structure of the dataset being tested, suggesting that the 
less arbitrary method of F-measure optimization to determine significance threshold is preferable. 
Conclusion: Therefore, we suggest using F-measure optimization instead of placing an arbitrary 
threshold to evaluate the significance of Gene Ontology Enrichment results, and using resampling to 
replace analytical methods 
Keywords: Gene Ontology; F-measure; False Discovery Rate; Microarray Data Analysis 
 
Background 
Gene Ontology (GO) enrichment analysis is a powerful tool to interpret the biological 
implications of selected groups of genes. The gene lists from experiments such as microarrays, are 
gathered into clusters associated with biological attributes, and defined as GO terms1. The GO terms 
are arranged in an acyclic tree structure from more specific to more general descriptions, including 
biological process (BP), cellular component (CC), and molecular function (MF). GO aspires to create 
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a formal naming system to define the biologically significant attributes of genes across all organisms. 
Each enriched GO term derived from a list of genes is evaluated by its significance level, i.e. the 
probability that the measured enrichment would be matched or exceeded by pure chance. 
Enrichment tools have been developed to process large gene lists to generate significantly 
enriched ontologies. Huang et.al (2009) summarizes the tools widely used for GO enrichment2 . 
Different tools emphasize different features. Gorilla3, DAVID4, g:profiler5 are web interfaces that 
integrate functional annotations including GO annotations, disease and pathway databases etc. 
Blast2GO6 extends annotation of gene list to non-model organisms by sequence similarity. GO-Miner7, 
Babelomics8, FatiGO9, GSEA10,11, and ErmineJ12 apply resampling or permutation algorithms on 
random sets to evaluate the number of false positives in computed gene ontologies associated with test 
sets. DAVID 4 and Babelomics8 introduced level-specific enrichment analysis; that is, not including 
both parents and children terms. TopGO contains options, “eliminate” and “parent-child”, which 
eliminate or reduce the weight of genes in the enriched children terms when calculating parent term 
enrichment13. TopGO14  and GOstats15  provide R-scripted tools for ease of further implementation.  
Cytoscape plugin in BinGO 16 is associated with output tree graphs.  
To calculate raw p-values for GO enrichment without multiple hypothesis correction, methods 
used include exact or asymptotic (i.e. based on the hypergeometric distribution or on Pearson's 
distribution), one- or two-sided tests17. Rivals et. al. discussed the relative merits of these methods17.   
Generally, inference of the statistical significance of observed enrichment of categories in gene 
ontology databases can’t be assumed to be parametric, because there is no a priori reason to postulate 
normal distributions within gene ontology terms.  Randomization methods are powerful tools for 
testing nonparametric hypotheses18.  However, heuristic methods for testing nonparametric hypotheses 
have long been widely used due to lack of adequate computational resources for randomization tests. 
In gene ontology enrichment, a widely-used heuristic method is that of Benjamini and Hochberg19.  In 
their original paper, Benjamini and Hochberg tested their method against a more computationally 
intensive resampling procedure for selected input data and found no significant difference, Thus the 
more computationally efficient Benjamini-Hochberg method was justified. 
Benjamini-Hochberg has been widely applied in enrichment tools such as BinGO16, DAVID4, 
GOEAST20, Gorilla3, and Babelomics8, to name a few. The similar Benjamini-Yekutieli method is 
included in the GOEAST package which enables to control the FDR even with negatively correlated 
statistics20 21. A recent approach published by Bogomolov, et.al. (2017) deals with multiple hypothesis 
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correction and error control for enrichment of mutually dependent categories in a tree structure using 
a hierarchical Benjamini-Hochberg-like correction22. Gossip provides another heuristic estimation of 
false positives that compares well with resampling in the situations tested23. 
A randomized permutation method for assessing false positives is embedded in the protocol of 
Gene Set Enrichment Analysis (GSEA)10.  Kim and Volsky24 compared a parametric method (PAGE) 
to GSEA and found that PAGE produced significantly lower p-values (and therefore higher putative 
significance) for the same hypotheses.  They suggest that PAGE might be more sensitive because 
GSEA uses ranks of expression values rather than measured values themselves.  However, they do not 
demonstrate that the hypothesis of normal distributions in gene ontology databases that underlies 
PAGE is generally true. 
Noreen25 considered the potential of using more widely available computer power to do exact 
testing for the validity of hypotheses, in order to be free of any assumptions about the sampling 
distributions of the test statistics, for example the assumption of normality.  The essence of the more 
exact methods is the generation of a null hypothesis by the creation and analysis of sets of randomly 
selected entities (null sets) that are of the same type as the test set. Then the extent to which the null 
hypothesis is rejected emerges from comparing the results of conducting the same analysis on the null 
sets and the test set.  As exemplified by the over one thousand citations of this work by Noreen, these 
methods have been widely adopted in many areas in which complex datasets must be mined for 
significant patterns, as for example in financial markets.     
In the present paper we utilize a straightforward random resampling method for creation of null 
sets and compare resultant assessments for estimating false positives with commonly used analytical 
methods as applied to gene ontology enrichment analysis.  We also evaluate the computational cost of 
this method relative to analytical methods. 
In applying all the cited methods and tools, it is common to apply a threshold boundary between 
"significant enrichment" and "insignificance".  Such assignment to one of two classes is an example 
of a binary classification problem. Often such classifications are made utilizing an optimum F-
measure26. Rhee, et.al. (2008) have suggested application of F-measure optimization to the issue of 
gene ontology enrichment analysis27. In the present work, we present an approach to gene enrichment 
analysis based on F-measure optimization, which considers both precision and recall and provides a 
flexible reasonable threshold for data sets depending on user choice as to the relative importance of 
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precision and recall. We also compare a resampling method to the Benjamini-Hochberg method for 
estimation of FDR and use with F-measure optimization.   
We also consider the argument made by Powers 26 that the F-measure is subject to biases, and 
that instead of precision and recall (the constituents of the F-measure) the constructs of markedness 
and informedness should be considered.  Whereas precision and recall are entirely based on the ability 
to identify positive results, informedness and markedness give equal weight to identification of 
negative results.   We note that the Matthews Correlation Coefficient (MCC), another well-vetted 
measure of significance28, is the geometric mean of the markedness and informedness. 
Our results in this paper will suggest that resampling is preferable to analytical methods to 
estimate FDR, since the compute costs are modest by today’s standards and that even well-accepted 
and widely used analytical methods may have significant error.  Our results also suggest that F-measure 
or MCC optimization is preferable to an arbitrary threshold when classifying results as “significant” 
or “insignificant”.  For the particular analyses in this paper, we found no significant difference in 




For results reported in this study (described below), the TopGO14  package is implemented to 
perform GO enrichment analysis, using the “classic” option.  In this option, the hypergeometric test is 





The empirical resampling and Benjamini-Hochberg (BH) methods are used to estimate the 
FDR. The p-value adjustment using Benjamini-Hochberg is carried out by a function implemented in 
the R library. http://stat.ethz.ch/R-manual/R-devel/library/stats/html/p.adjust.html  
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The resampling method is based on the definition of p-value as the probability that an observed 
level of enrichment might arise purely by chance. To evaluate this probability, we generate several null 
sets, which are the same size as the test set. The genes in the null sets are randomly sampled from the 
background/reference list. GO enrichment analysis was carried out on both test set and null set. The 
average number of enriched results in the null sets would be the false positives. In all the results shown 
in this paper, 100 null sets were used to compute the average, unless otherwise indicated.  In the 
pipeline, available for download in Supplementary material, the number of null sets is an adjustable 
parameter.  The ratio of false positives to predicted positives is the FDR. 
 
F-measure Optimization and the Matthews correlation coefficient.  
To evaluate F-measure and MCC, we started with evaluating true/false positive/negatives and 
the metrices derived from the true/false positive/negatives. The number of "predicted positive" is the 
number of GO terms found at a threshold. For an analytical method such as BH, the "false positive" 
would be (predicted positive) multiply by FDR, which is estimated by the corrected p-value. For 
resampling, the "false positive" would be the average number of GO terms found by null sets. The 
"true positive" is calculated by: 
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 =  (𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒)  − (𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒) 














“Real Positive” is defined by 
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𝑅𝑒𝑎𝑙 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 =  𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 +  𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 
In the absence of the ability to calculate “False Negatives” directly, we estimate the number of 
real positives as the maximum true positive achieved across the range of possible p-values.  This 
procedure is shown graphically in Figure 1 for the BH method of computing false positives, using as 
an example a gene list to be described in detail later in the paper.  In this figure we plot predicted 
positives, false positives (False Discovery Rate x predicted positives), and true positives (predicted 
positives – false positives) vs. uncorrected p-value for the entire range of p-values from 0 to 1. At very 
lenient p-values the FDR approaches 1, resulting in the true positives approaching 0. It is difficult to 
evaluate false negatives and thus assign a number for “real positives”, since a false negative is an object 
that escaped observation, and thus can’t be counted directly.  Yet such estimation is essential to 
applying F-measure.  In our case, if we follow the trajectory of the true positives in Figure 2.1 as the 
threshold is relaxed, we see that at very stringent p-values all positives are true positives.  As the 
threshold is relaxed further, more false positives are generated, so the predicted positive and true 
positive curves start to diverge.  At p = 0.13 (a far higher value than would ordinarily be used as a 
cutoff) the true positives reach a maximum, and the number of true positives starts to decline as p is 
further relaxed.  We utilize this maximum value as the maximum number of GO categories that can be 
possibly regarded as enriched in the data set; i.e., the number of real positives. 
Based on precision and recall at each raw p-value cut-off, we can obtain a table and curve of 
F-measure vs uncorrected p-value. The F1-measure is an equally weighted value of precision and recall. 
A generalized F-measure introducing the parameter  can be chosen based on the research question, 
whether minimization of type I (false positive) or type II (false negative) error, or balance between the 
two, is preferred, according to the equation: 




 Equation 1 
The larger the magnitude of  the more the value of F is weighted towards recall; the smaller 
the value of  the more the value of F is weighted towards precision.  Optimizing F-measure provides 
us a threshold which emphasize precision (<1) or recall (>1), or balance of both (=1).   Note that 
precision and recall are extreme values of F-measure; that is, Precision=F0 and Recall=F∞. 
To compare the different thresholds, we also calculated for each of them the Matthews 
correlation coefficient (MCC) 28. Originally developed to score different methods of predicting 
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secondary structure prediction in proteins, the MCC has become widely used for assessing a wide 
variety of approaches to binary classification, as exemplified by the 2704 citations (at this writing) of 
the original paper. Perhaps even more telling, the citation rate for the seminal MCC paper has been 
increasing as the method is being applied in a greater variety of contexts, reaching 280 citations in 
2017 alone.  
In the expression below for the MCC, the True Negative (TN) is estimated using total number 




 Equation 2 
The MCC can be expressed in an equivalent expression using definition of informedness and 
markedness, which includes precision and recall, as well as the inversed precision and recall evaluating 








                  Equation 4 
𝑖𝑛𝑓𝑜𝑟𝑚𝑒𝑑𝑛𝑒𝑠𝑠 = 𝑟𝑒𝑐𝑎𝑙𝑙 + 𝑖𝑛𝑣𝑅𝑒𝑐𝑎𝑙𝑙 − 1            Equation 5 
𝑚𝑎𝑟𝑘𝑒𝑑𝑛𝑒𝑠𝑠 = 𝑝𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 + 𝑖𝑛𝑣𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 − 1    Equation 6 
Combining Equations 2-6 and some algebra we find: 
𝑀𝐶𝐶 = √𝑚𝑎𝑟𝑘𝑒𝑑𝑛𝑒𝑠𝑠 ∙ 𝑖𝑛𝑓𝑜𝑟𝑚𝑒𝑑𝑛𝑒𝑠𝑠 Equation 7 
 
In an analogous fashion to the manner in which the F-measure may be generalized to weight 
either precision or recall more strongly by a variable , so also the MCC can be generalized to more 
strongly weight either markedness or informedness by the expression 
𝑀𝐶𝐶 = √𝑚𝑎𝑟𝑘𝑒𝑑𝑛𝑒𝑠𝑠 × 𝑖𝑛𝑓𝑜𝑟𝑚𝑒𝑑𝑛𝑒𝑠𝑠𝛽
1+𝛽
       Equation 8 
Data Sets 
• Environmental Stress Response (ESR) 
First dataset is the Yeast Environmental Stress Response (ESR) data 29, a robust data set for a 
model organism. The ESR set is list of genes commonly differentially expressed in response to 
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environmental stresses such as heat shock, nutrient depletion, chemical stress, etc. Approximately 300 
genes are up-regulated, and 600 genes are down-regulated in the ESR set.  We expect this set to be 
“well-behaved” (give reasonable results with standard methods of analysis), since the data come from 
a very well annotated model organism subject to a widely studied experimental intervention.   
• Alarm Pheromone (AP) 
The second data set is comprised of human orthologs to the honey bee Alarm Pheromone set30. 
The Alarm Pheromone set is a list of genes differentially expressed in honey bee brain in response to 
the chemical alarm pheromone, which is a component of the language by which honey bees 
communicate with each other. Previous studies have shown that the Alarm Pheromone set is enriched 
in placental mammal orthologs, compared to other metazoans including non-social insect orthologs31. 
The Alarm Pheromone set is much smaller than the ESR set, with 91 up-regulated genes and 81 down-
regulated genes. We expect the AP set to be not so “well-behaved” compared to the ESR set, as we are 
using model organism orthologs (human) to a non-model organism (honey bee) and the organisms 
diverged about 600 million years ago. 
• Random Test Sets 
To generate a baseline of the analysis for each data set using different FDR calculation methods, 
we have applied the pipeline to analyze randomly-generated sets as “test” set inputs, where FDR should 
equal to 1 for all uncorrected p-values.  
The BH FDR curves are calculated in the following way: The R program p.adjust is applied to 
generate a list of analytically calculated FDR (BH) corresponding to uncorrected p-values for each 
“test” sets. Then the lists of FDRs are merged and sorted by uncorrected p-values. The FDRs are 
smoothed by a “sliding window” method: at each uncorrected p-value point, the new FDR is the 
average value of 11 FDRs centered by the uncorrected p-value point.  
The Resampling FDR curves are calculated in the following way: The output uncorrected p-
values are binned in steps of 1E-4. The counts below the upper bound of each p-value bin for the “test” 
set enrichment categories are the “Predicted positives”, and average counts for the null set enrichment 
categories are the “False Positives”. The process is repeated for the multiple “test” sets, and 
corresponding to each test set, 100 null sets were generated for “False Positive” calculation. Then the 
number of total and false positives are averaged, respectively. The FDR would be the quotient of the 




In this section, we present the results of applying our methods to the two previously published 
sets of data introduced in the Methods section, the ESR set and the human orthologs of the Alarm 
Pheromone set. For both above data sets, we show the results from analyzing the genes using the 
biological process (BP) category of the gene ontology.  These results will show 1) areas of agreement 
and difference between Benjamini-Hochberg and random resampling in evaluation of FDR, 2) how 
the assessment of significance of enrichment varies according to the particular database that is being 
probed, and 3) how the assessment of significance of enrichment varies according to the weight 
assigned to precision vs. recall.  
ESR Set (Environmental Stress Response, yeast)  
• Benjamini-Hochberg (BH) 
Figure 2.2 shows the results of F-measure optimization on the ESR data based on FDR 
calculated by Benjamini-Hochberg (BH) method.  As expected by their definitions, precision (F0) 
decreases with increasing p-value while recall increases with increasing p-value.  F0.5 (precision-
emphasized), F1 (precision and recall equally weighted) and F2 (recall-emphasized) all show relative 
maxima, providing a rational basis for assigning a threshold for significance. The horizontal scale is 
extended far enough to visualize the determination of the number of real positives.  In the case of the 
up-regulated gene set, maximum F1 occurs at an uncorrected p-value close to 0.05.  In the case of the 
down-regulated gene set however, it appears that a much more stringent cutoff would be appropriate.   
• Resampling 
Figure 2.3 shows the results of F-measure optimization on the ESR data using resampling to 
calculate FDR. The false positives are calculated by average number of GO categories enriched in 
random sets. For the up-regulated set, all the F-measures optimize at much lower uncorrected p-values 
than do the F-measures calculated by the BH method. For the down-regulated set, resampling-
calculated F0.5 is optimized at a lower uncorrected p-value than BH method while F1 and F2 are 
optimized at slightly higher uncorrected p-value. 
Comparing the results in Figure 2.2 and Figure 2.3 show that the optimum cutoff (as measured 
by maximum F1) varies widely, depending on the gene set to be tested and the method for assessing 
FDR.  Using BH the optimum cutoff is .0476 for upregulated ESR and .012 for downregulated ESR.  
Using resampling, the optimum cutoff is .0096 for upregulated ESR and .0126 for downregulated ESR.  
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Also, as expected, the optimum cutoff is relaxed when recall is emphasized (F2 instead of F1)   and 
made more stringent when precision is emphasized (F0.5 instead of F1).   
 
Alarm Pheromone Set (human orthologs)  
• Benjamini-Hochberg (BH) 
Figure 2.4 shows exactly the corresponding results as Figure 2.2, this time on the human 
orthologs to the honey bee alarm pheromone set.  F-measures are maximized at much higher thresholds 
than for the ESR set.  The difference in optimal F-measure is largely due to the different shapes of the 
recall curves.  For the ESR set, precision drops significantly more rapidly with increasing uncorrected 
p-value than does the AP set.  Therefore, a higher uncorrected p-value can be used for the latter set 
with essentially the same degree of confidence.  
• Resampling 
Figure 2.5 shows the number of GO categories and F-measures for the alarm pheromone set 
human orthologs using resampling method. The resampling method have found more false positives 
than BH, and therefore the precision is much lower than the precision calculated from BH, and the F-
measures are optimized at lower uncorrected p-values than the F-measures calculated from BH. 
From the above Figures 2.2-2.5, we can note the stepped structure in the number of enriched 
GO categories. The stepped structure lies in the fact that the number of genes associated with any GO 
category, in the test set or reference set, must be an integer with limited number of choices. Therefore, 
the uncorrected p-values calculated would be in a discrete set instead of a continuum. Consequently, 
the number of positives as a function of p-values increases in a stepped way. As a result, the F-measures 
derived from the number of GO categories have spikes. But as our graphs have demonstrated, the 
optimal F-measures reflect the different weights on precision and recall despite the spikes. 
Comparing the results in Figures 2.4 and 2.5 shows that, for the AP gene sets as for the ESR 
gene sets, the optimum cutoff threshold is different for the upregulated and downregulated gene sets 
and also is different when BH is used to determine the FDR as compared to resampling. 
 
Comparison of F-Measure with MCC for Optimization of Threshold Choice 
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As indicated in the section on methods, a widely used alternative to the F-measure for 
optimization is the Matthews Correlation Coefficient (MCC) which, unlike the F-measure, gives equal 
weight to negative as well as positive identifications.  Figure 2.6 shows MCC optimization for exactly 
the same data set (ESR) and False Discovery Rate determination (Resampling) as in Figure 2.5. The 
most important lesson from this Figure is that the uncorrected p-value that maximizes MCC1 is the 
same as the uncorrected p-value that maximizes F1.  Inspection of the formulas reveals the reason.  The 
divergence between MCC and F-measure occurs only when the false negatives are a significant fraction 
of the total negatives.  Since there are tens of thousands of terms in the gene ontology database this 
condition does not pertain to our situation, so optimization of the F-measure is an adequate strategy.  




Comparison of FDR (False Positive) Calculation by Benjamini-Hochberg (BH) and 
Resampling 
In the previous section, we have demonstrated how to use F-measure optimization to obtain a 
flexible threshold based on whether precision or recall is more heavily weighted by the researcher.   In 
that section the FDR is calculated but not shown explicitly.  The present section explicitly compares 
the FDR as calculated by the BH method and by random resampling. In each case the random 
resampling FDR is computed based on the average of 50 randomly sampled null sets of the same size 
as the test set.  Figure 2.7 shows that for the ESR set, the BH method and resampling estimate similar 
FDR at low p-value. As the threshold increases, the BH method estimates lower false discovery rate, 
and therefore higher precision, than the resampling method at the same uncorrected p-value. By 
contrast, for the Alarm Pheromone set, the BH method estimates lower FDR than resampling.  
To further evaluate the methods, we carried out multiple runs using random (null) sets as test 
sets. In this case, the FDR should in principle be 1, for any uncorrected p-value. The results of this test 
are shown in Figure 8a, where for each segment of p-values (bin size = 0.0001) we show the mean 
plus/minus the standard deviation. The resampling method passes the test on the average, but the results 
are noisy.  The BH method systematically underestimates FDR. Figure 7b shows that the noise in the 
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resampling method results in Figure 7a are largely due to the variation in the random null sets, and that 
the noise level in using random resampling for real data is acceptably low. 
Statistical Summary of Results from Different Threshold Criteria. 
Table 2.1 shows the statistical summary of using all different criteria for the distinction between 
significant and non-significant enrichment.  Notable features of this table include: 1) Variation of the 
threshold within the range explored in this study made relatively little statistical difference for the ESR 
set.  Over the entire range of thresholds, both the precision and the recall for the ESR set are good, and 
the number of terms returned does not change very much. 2) Variation of the threshold within the range 
explored in this study makes a very large difference in the results of the AP set.  For the most stringent 
choice of threshold, the precision is high, but the recall is quite low.   Relaxing the threshold improves 
the recall, but at a cost to the precision, so there is a distinct tradeoff between precision and recall, and 
3) We discovered that optimizing F1 is exactly equivalent to optimizing the Matthews correlation 
coefficient.  F.5 is optimized at a lower uncorrected p-value than F1 while F2 is optimized at a higher 
p-value, and the same pattern is seen for MCC. 
Identity of Enriched Terms Using Different Threshold Criteria. 
• Higher order relatively general terms. 
The enriched GO terms are categorized by their parent terms, 1st order parent being direct 
children of the root term “Biological Process” (GO:0008150), 2nd order parent being direct children of 
the 1st order parent terms. Each enriched GO term is traced back to the root by the shortest route.  
Tables 2.2 through 2.5 below provide an outline of the complete gene ontology results by showing the 
high order terms that are either themselves enriched according to the described criteria or have child 
terms enriched, or both.  In each case the results from three different thresholds are shown, BH 
FDR<.05, optimum F.5, and optimum F1.  The most striking pattern is that for the ESR sets (Tables 2.2 
and 2.3), modifying the threshold within the parameters of this paper did not change the identity of the 
putatively enriched higher order terms very much.  However, for the AP sets (Tables 2.4 and 2.5), 
relaxing the threshold caused a substantial increase in the number of high order terms judged to be 
putatively significant.  However, from Table 1 is it seen that the precision (confidence) of the additional 
terms for the AP sets is substantially lower than for the terms returned using the most stringent 
threshold.  Thus, for the AP set we clearly see that we can’t simultaneously have high precision and 
high recall.  We must trade one for the other. 
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• Relatively Specific Terms. 
Specific, or “child” terms returned in these calculations are too numerous to delineate 
completely in the body of the paper. They are instead provided in the spreadsheet 
“AllGOTermsInTree_Final (supplementary material 2.1)”  Separate tabs delineate the returns from 
ESR upregulated, ESR downregulated, AP upregulated, and AP downregulated.  Each entry in the 
spread sheet is color coded with the code given in the tab labeled “color coding”.  Entries that are 
shaded are either primary or secondary (more general) classes, which will also be shown in Table 2.1.  
Entries colored in black appear at "standard" threshold: BH FDR<0.05.  Entries colored in blue emerge 
at the threshold determined by optimal F0.5. For AP Up, the standard threshold is the most stringent 
while for all other sets, the optimal F0.5 is the most stringent. Entries colored in red first emerge at the 
least-stringent threshold for that data set, which corresponding to optimal F1. The format of the 
spreadsheet for each of the data sets is as follows: Column A is the identifying number of the GO class 
that is returned as significant, column B is the name of that class, and column C is the raw enrichment 
p-value for that class. Column D is non-zero only for the rows belonging to primary or secondary GO 
classes (which are shown explicitly in Tables 2.2-2.5 for the four data sets). The numerical value in 
column D represent the smallest uncorrected p-value of all the classes under the primary or secondary 
class shown in that row. The spread sheet is organized to be sectioned off according to primary or 
secondary classes. To illustrate the sectioning, under the “AP up” is the primary class “cellular process” 
and immediately under that the secondary class “protein folding”.  This is followed by more specific 
classes under “protein folding” such as “chaperone-mediated protein folding” and others. The columns 
E and farther to the right are GO numbers representing the lineage of the particular term in that row 
starting with the primary class and continuing to the particular term in that row. 
Because the trade-offs with varying threshold are most clear with the AP sets, we select those 
now for discussion. One biologically interesting feature emerging from varying the threshold consists 
of the more specific GO classes emerging from general classes already identified with a more stringent 
threshold.  For example, in the “AP up” set “protein folding” was identified as a secondary class of 
interest by virtue of a very strong enrichment score. On relaxing the threshold more specific “child” 
classes emerged, such as “chaperone cofactor-dependent protein folding”, “endoplasmic protein 
folding”, and others.  While these more specific classes are identified with less confidence than the 
overall “protein folding” class they are subsumed into, they do provide the most likely subclasses 
within protein folding to be biologically meaningful.  Similarly, under the secondary class of “signal 
transduction” more specific subclasses such as “ER-nucleus signaling pathway”, “stress-activated 
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MAPK cascade” and others emerge with modest threshold relaxation.   This pattern is seen throughout 
the spreadsheet.  Relaxing the threshold provides not only improved recall, but improved specificity, 
which will help in biological interpretation of GO enrichment results. 
• Summary 
In general, when thresholds are varied, a tradeoff can plainly be seen between precision and 
recall.  When looking at the specific GO classes that are returned at different choices of threshold a 
second tradeoff emerges, between generality and specificity. As threshold is relaxed some more 
general terms are revealed, but the greater effect is that more specific terms are revealed within general 
terms that were suggested at more stringent thresholds.  These specific terms can help to provide a 
more focused interpretation of the biological results.   
Conclusions 
In this work, we have addressed two issues with the commonly used methods in the GO 
enrichment analysis: the relationship between resampling vs. Benjamini-Hochberg theory for 
estimating false discovery rate, and the arbitrariness of the threshold for significance. 
To consider resampling vs. Benjamini-Hochberg we made five independent comparisons.  Four 
consisted of upregulated and downregulated genes separately for two different animal experiments.  
The fifth was an array of random gene lists (null sets).  For the yeast ESR sets the two methods gave 
almost the same results for uncorrected p-value<.04 but diverged substantially for more relaxed p-
values, with the BH underestimating the FDR.  For the honeybee AP set the BH method underestimated 
the FDR significantly at all uncorrected p-values.  For the random or null sets, we know that the correct 
FDR is 1, because there is no significance to the results. Yet for the null sets the BH method produced 
FDR<1 by a large margin for the full range of uncorrected p-values.  By contrast the resampling 
method, although noisy, does not systematically deviate from 1 in its prediction of FDR for the null 
sets. 
It is of interest to consider why the BH method, while very useful and successful in some cases, 
sometimes fails.  It is understood that the method will always work when the true inferences are 
independent.  Strictly speaking, this will not be true of Gene Ontology data since many genes belong 
in multiple Gene Ontology categories.  However, Benjamini and Yekutieli21 showed that the method 
was still valid for dependent hypotheses provided that the related hypotheses that failed the null test 
showed positive regression of likelihoods. Consideration of the tree-like structure of Gene Ontology 
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data32 shows that this is true to a great extent. The branches of the tree-like structure clearly show 
positive regression within each branch; if a child category is enriched a parent is more likely to be 
enriched, and vice versa. Thus, as long as the enriched classes fall along a few well-delineated branches 
of the Gene Ontology tree structure, BH will work well. This appears to be largely the case for the 
yeast ESR set at relatively stringent p-values, in which the experimental intervention activated well-
defined and annotated pathways. Thus, for relatively stringent cutoffs the BH FDR works well for this 
data set. However, some genes are members of categories in multiple branches, compromising the 
positive regression criterion.  In the ESR set at relatively relaxed thresholds, and for the AP set at all 
thresholds, many Gene Ontology categories in different branches but with overlapping gene 
membership are represented in the returned categories, so that both independence and the positive 
regression criterion are violated. These considerations tell us why BH fails dramatically for the 
completely null sets. Neither independence nor positive regression are satisfied, except sometimes 
completely accidentally.  
For the issue of the arbitrariness of the threshold, we introduced optimization of F-measures so 
that both type I and II errors are considered. Unlike arbitrarily applied threshold of BH FDR<0.05 or 
uncorrected p-value<0.01 for any data set, the F-measure optimization approach provides a flexible 
threshold appropriate to the nature of the data set and the research question. If the data set is high in 
noise-to-signal ratio and the penalty for letting in false positive is high, we can choose to optimize F-
measures weighing more on precision. If the data set fails to show much enrichment by commonly-
applied methods, we can relax the threshold and extract the best information indicated by F-measure 
optimization.  
A concern is that, because of the nature of the problem, we were forced to use a heuristic (albeit 
reasonable) method to estimate the false negatives, essential for calculating recall.  We judge that this 
concern is more than offset by the advantage of enabling the replacement of an arbitrary threshold with 
F-measure optimization.   
We found that for the particular class of problems dealt with in this paper the F-measure is as 
appropriate an optimization criterion as the Matthews Correlation Coefficient. 
By examination of the specific GO categories that are returned by our analysis, we find that 
relaxing the threshold, we see revealed the most likely specific subcategories within the general 
categories that are revealed at the most stringent threshold.  Thus, varying the threshold not only 
reflects the tradeoff between precision and recall, but also between generality and specificity.  
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In the supplementary material we present the spreadsheet “AllGOTermsInTree_Final”, 
which shows all the specific GO terms returned in the work described in this paper.  Also, in the 
supplementary material, we present our automatic pipeline integrating TopGO with resampling and 
analyzing functions to carry out the whole process of resampling, enrichment analysis, F-measure 
calculation, and representing results in tables and figures. The pipeline also includes a GOstats15 
module for easy analysis of under-represented terms and a STRINGdb33  module for KEGG pathway 
terms. As demonstrated, the pipeline can also calculate analytical FDR including, but not limited to, 
the BH method.  
In summary, we suggest replacing a fixed p-value for assigning a threshold in enrichment 
calculations with an optimal F-measure, which incorporates the well-established and well-defined 
concepts of precision and recall.  
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0.00459 118 0.936 0.798 0.864 
 RS opt F0.5 0.0029 110 0.964 0.765 0.858 
 RS opt F1 0.0096 146 0.890 0.939 0.914 




0.00689 211 0.948 0.883 0.914 
 RS opt F0.5 0.0016 185 0.989 0.808 0.894 
 RS opt F1 0.0126 251 0.902 1 0.948 




0.00116 57 0.807 0.0974 0.290 
 RS opt F0.5 0.012 246 0.600 0.312 0.429 
 RS opt F1 0.0636 699 0.416 0.615 0.500 




0.00138 58 0.759 0.353 0.517 
 RS opt F0.5 4.00E-04 44 0.909 0.321 0.540 
 RS opt F1 0.0073 146 0.534 0.626 0.577 
 Max MCC 0.0073 146 0.534 0.626 0.577 
Table 2.1. Precision, Recall, and Matthews Correlation Coefficients (MCC) at thresholds BH 
FDR<0.05, Resampling optimal F0.5, and Resampling optimal F1. For the four data sets examined, we 
have found that optimal F1 is the position that MCC reaches maximum.  This correspondence between 
optimum F1 and optimum MCC was unanticipated but emerged from independent calculation of both 
quantities. For the ESR set, the MCC is high for all thresholds. For AP set, MCC is relatively low, and the 





GO ID Parent Term Minimum raw p-value of child terms 
GO:0008152 Metabolic Process (80,85,100) 3.40E-13 
GO:0050896 response to stimulus (22,23,26) 7.40E-13 
GO:0065007 biological regulation (4,5,7) 9.00E-05 
GO:0009987 cellular process (4,5,13) 0.00035 
**GO:0032502 developmental process (0,0,1) 0.00589 
Table 2.2. ESR, Up-regulated Set Each row corresponds to a 1st order Parent Terms of enriched 
GO categories of ESR set, Up regulated genes. The three numbers in parentheses reflect the total number 
of terms in the Parent family (Parent plus children).  We found no difference in the high order terms between 
BH FDR<.05 and F.5. However, the developmental process parent term (labeled with “**”) emerges when the 
threshold is increased to optimal resampling F1.  The groupings as defined by the parent terms do not change 
very much, but the number of more specific child terms increases moderately.  
 
GO ID Parent Term 
Minimum raw p-value of child 
terms 
GO:0008152 Metabolic Process (120,139,168) 1.00E-30 
GO:0009987 Cellular process (6,6,7) 1.00E-30 
GO:0071840 
Cellular component organization or 
biogenesis (31,32,36) 
1.00E-30 
GO:0051179 Localization (21,22,22) 5.20E-28 
GO:0065007 biological regulation (7,11,15) 3.20E-12 
*GO:0050896 response to stimulus (0,1,2) 0.00357 
Table 2.3. ESR, Down-regulated Set 1st order Parent Terms of enriched GO categories of ESR 
set, down regulated genes. For this data set the optimum F .5 was more stringent than the BH FDR <.05.  The 
term “response to stimulus” (labeled with “*” does not meet the optimum F .5 criterion but does for the other 
two criteria. The numbers in the parentheses refer to the numbers of enriched terms in each parent category, 
ordered from low to high. As with the up-regulated genes, relaxing the threshold did not change the parent 






GO ID Parent Term Minimal raw p-value of child terms 
GO:0009987 Cellular process (13,36,96) 1.10E-10 
GO:0050896 Response to stimulus (57,71,119) 1.40E-08 
GO:0065007 Biological regulation (28,113,288) 4.30E-05 
GO:0008152 Metabolic process (9,44,113) 5.00E-05 
GO:0032502 Developmental process (1,9,33) 0.00043 
GO:0071840 
cellular component organization or 
biogenesis (1,6,12) 
0.00102 
*GO:0051179 Localization (0,8,37) 0.00138 
*GO:0022414 reproductive process (0,2,7) 0.00192 
*GO:0002376 immune system process (0,2,8) 0.00504 
*GO:0032501 
multicellular organismal process 
(0,5,19) 
0.00509 
*GO:0040011 Locomotion (0,1,2) 0.00932 
**GO:0051704 multi-organism process (0,0,11) 0.02 
**GO:0008283 cell proliferation (0,0,2) 0.02962 
Table 2.4. 1st order Parent Terms of enriched GO categories of AP set, Up regulated genes. The 
terms with “*” appears when the threshold is increased from BH FDR<0.05 (uncorrected p-value<0.00116) to 
optimal resampling F0.5-measure (uncorrected p-value<0.012). Terms with “**” emerges when the threshold 
is increased to that for optimal resampling F1(uncorrected p-value<0.0096). The number in the brackets refers 
to the number of enriched terms within each parent category at each threshold, ordered from low to high . 
Unlike the ESR sets, for this data set relaxing the threshold caused significantly greater returns in both general 






GO ID Description Minimal p-value of child terms 
GO:0008152 Metabolic Process (40,7,25) 3.20E-08 
GO:0009987 cellular process (3,4,13) 7.00E-06 
GO:0071840 
cellular component organization or 
biogenesis (1,0,5) 
7.90E-06 
*GO:0051179 Localization (0,3,16) 0.00052 
**GO:0065007 biological regulation (0,0,15) 0.00145 
**GO:0050896 response to stimulus (0,0,7) 0.00174 
**GO:0022414 reproductive process (0,0,1) 0.00441 
**GO:0051704 multi-organism process (0,0,1) 0.00441 
**GO:0032501 
multicellular organismal process 
(0,0,3) 
0.00441 
**GO:0032502 developmental process (0,0,1) 0.00534 
Table 2.5. 1st order Parent Terms of enriched GO categories of AP set, Down regulated genes. 
The terms with “*” disappears when the threshold is decreased from BH FDR<0.05 (uncorrected p-
value<0.00138) to optimal resampling F0.5-measure (uncorrected p-value<4.00E-4). Terms with “**” emerges 
when the threshold is increased at optimal resampling F1(uncorrected p-value<0.0073). The number in the 
brackets refers to the number of enriched terms at each threshold, low to high.  Unlike the ESR sets, for this 
set relaxing the threshold caused substantial increases in the putative enriched categories at both the general 







Figure 2.1. Number of positives for the yeast environmental stress response (ESR) set over the 
full range of uncorrected p-values from 0 to 1. “Predicted positives” is the number of Biological Process 
GO categories returned as a function of the p-value threshold for significance.  “False Positives” is the number 
of predicted positives multiplied by the False Discovery Rate as calculated by the Benjamini -Hochberg 
formulation.  “True Positives” is “Predicted Positives” minus “False Positives”.  “Real Positives”, nec essary 






Figure 2.2. Number of positives and F-measure values for ESR set, BH-estimated FDR. a) Shows 
the number of enriched biological process Gene Ontology categories as a function of uncorrected p-value, the 
Benjamini-Hochberg number of false discoveries, and the projected true positives, namely the difference 
between the predicted positives and the false positives, for the upregulated ESR gene set. This panel is from 
the same data set at Figure 1. The number pairs in parenthesis are respectively (uncorrected p-value 
maximizing F0.5, number of true positives at that p-value), (uncorrected p-value maximizing F1, number of 
true positives at that p-value), (uncorrected p-value maximizing F2, number of true positives at that p-value), 
(uncorrected p-value maximizing true positives, number of true positives at that p-value) b) is the same as a) 
for the downregulated gene set. c) shows the F-measures computed from a) and d) the F-measures computed 
from b). Number of real positives, necessary to calculate recall (and therefore (F -measure)), is approximated 
by (predicted positives – false positives) max. The p-value at which the computed true positives are a maximum 
is 0.13 for upregulated gene list (a) and at 0.099 for downregulated gene list. (b) The pairs of numbers in 
parenthesis in a) and b) indicate the p-value and number of returned GO terms at significant markers, 
specifically at maximum F0.5 (emphasizing precision), F1 (balanced emphasis between precision and recall), 





Figure 2.3. Number of positives and F-measure values for ESR set, Resampling-estimated FDR. 
a) Shows the number of enriched biological process Gene Ontology categories as a function of uncorrected p-
value, the average number of enriched Gene ontology categories from the random set as the false positi ves, 
and the projected true positives, namely the difference between the predicted positives and the false positives, 
for the up-regulated ESR gene set. The number pairs in parenthesis are respectively (uncorrected p-value 
maximizing F0.5, number of true positives at that p-value), (uncorrected p-value maximizing F1, number of 
true positives at that p-value), (uncorrected p-value maximizing F2, number of true positives at that p-value), 
(uncorrected p-value maximizing true positives, number of true positives at that p-value) b) is the same as a) 
for the down-regulated gene set. c) shows the F-measures computed from a) and d) the F-measures computed 
from b). Number of real positives, necessary to calculate recall (and therefore (F -measure)), is approximated 
by (predicted positives – false positives) max. The p-value at which the computed true positives are a 
maximum is 0.021 for upregulated gene list (a) and 0.0179 for downregulated gene list. (b) The pairs of 
numbers in parenthesis in a) and b) indicate the p-value and number of returned GO terms at significant 
markers, specifically at maximum F0.5 (emphasizing precision), F1 (balanced emphasis between precision and 
recall), F2 (emphasizing recall), and Recall (where we obtain an estimation of relevant elements by 




Figure 2.4. Number of positives and F-measure values for Alarm Pheromone set, BH-estimated 
FDR. a) shows the number of enriched biological process Gene Ontology categories as a function of 
uncorrected p-value, the Benjamini-Hochberg number of false discoveries, and the projected true positives, 
namely the difference between the predicted positives and the false positives, for the upregulated alarm 
pheromone human orthologs gene set. The number pairs in parenthesis are respectively (uncorrected p-value 
maximizing F0.5, number of true positives at that p-value), (uncorrected p-value maximizing F1, number of 
true positives at that p-value), (uncorrected p-value maximizing F2, number of true positives at that p-value), 
(uncorrected p-value maximizing true positives, number of true positives at that p-value) b) is the same as a) 
for the downregulated gene set. c) shows the F-measures computed from a) and d) the F-measures computed 
from b). Number of real positives, necessary to calculate recall (and therefore (F-measure)), is approximated 
by (predicted positives – false positives) max. The p-value at which the computed true positives are a 
maximum is 0.391 for upregulated gene list (a) and at 0.292 for downregulat ed gene list. (b) The pairs of 
numbers in parenthesis in a) and b) indicate the p-value and number of returned GO terms at significant 
markers, specifically at maximum F0.5 (emphasizing precision), F1 (balanced emphasis between precision and 





Figure 2.5. Number of Positives and F-measure values for AP set, Resampling-estimated FDR. 
The figure shows the number of enriched biological process Gene Ontology categories as a function of 
uncorrected p-value, the average number of enriched Gene ontology categories from the random set as the 
false positives, and the projected true positives, namely the difference between the predicted positives and the 
false positives, for the up-regulated alarm pheromone human orthologs gene set. b) is the same as a) for the 
down-regulated gene set. c) shows the F-measures computed from a) and d) the F-measures computed from 
b).   Number of real positives, necessary to calculate recall (and therefore (F-measure)), is approximated by 
(predicted positives – false positives) max. The p-value at which the computed true positives are a maximum is 
0.596 for upregulated gene list (a) and at 0.065 for downregulated gene list. (b) The pairs of numbers in 
parenthesis in a) and b) indicate the p-value and number of returned GO terms at significant markers, 
specifically at maximum F0,5 (emphasizing precision), F1 (balanced emphasis between precision and recall), 





Figure 2.6. Number of Positives and MCC-measure values for AP set, Resampling-estimated 
FDR. This figure is the same as Figure 5 except that the optimization to determine significance-insignificance 
threshold is Matthews Correlation Coefficient (MCC) rather than F-measure. Note that the uncorrected p-
value threshold for optimum MCC1 is the same as for F1. Examination of the expressions for the two quantities 
shows that the reason for the convergence is that in this case the number of false negatives is very small 
compared to the number of total and true negatives, so the fractional variation in true negatives is very small.  




Figure 2.7. False discovery rate comparison. False discovery rate estimated by Benjamini-
Hochberg (solid curve) and Resampling (dashed curve) for the ESR set and Alarm Pheromone set. Figure 7 
compares the number of false discovery rate calculated by Benjamini-Hochberg (solid) and Resampling 
(dashed) in each set: a) up-regulated ESR, b) down-regulated ESR, c) up-regulated Alarm Pheromone set, and 
d) down-regulated Alarm Pheromone set. Generally, resampling has found higher false discovery rate than 
Benjamini-Hochberg. At low p-values, the BH and resampling methods get similar estimation of false 





Figure 2.8. Comparison of different FDR calculation method on accuracy and convergence. a) 
Comparison of BH and Resampling on random “test” sets.  At each p-value (p-values binned at intervals 
of .0001), the mean and standard deviation are calculated and plotted as shown. The random test sets consist 
of 281 yeast genes, against the background of the entire yeast genome. For each of the methods 50 test sets 
were used and the mean plus/minus standard deviation plotted as shown. Resampling hits the mark on the 
average but with substantial noise, while BH systematically underestimates FDR. b) Evaluation of resampling 
convergence on a real data set, ESR upregulated considered in this paper.  This set is run against five different 
ensembles of null sets, each ensemble containing 100 null sets.  The mean and standard deviation are plotted 
and compared to the results from the random test sets.  It is seen that the noise of the resampling method on a 





Additional file 2.1--- AllGOTermsInTree_Final.xlsx 
This is the spreadsheet showing all enriched terms at thresholds: BH FDR<0.05, optimal F0.5, and optimal 
F1. The terms are arranged by the primary and second-order parent terms. 
 
Additional file 2.2 --- pipelinemanual .docx  
“A TopGO- and GOstats-based automated pipeline for GO enrichment analysis using F-measure 
optimization based on resampling and traditional calculation”  
This is a word document giving detailed description of how to run the pipeline for resampling or 
analytical FDR calculation and obtain thresholds maximizing F-measures  
 
Additional file 2.3 --- pipeline.gz 
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Abstract 
Lithium has many widely varying biochemical and phenomenological effects, suggesting 
that a systems biology approach is required to understand its action. Multiple lines of evidence 
point to lithium intake and consequent blood levels as important determinants of incidence of 
neurodegenerative disease, showing that understanding lithium action is of high importance. In 
this paper we undertake first steps towards a systems approach by analyzing mutual enrichment 
between the interactomes of lithium-sensitive enzymes and the pathways associated with affective 
and neurodegenerative disorders. This work integrates information from two important databases, 
STRING and KEGG pathways. We find that for the majority of neurodegenerative disorders the 
mutual enrichment is many times greater than chance, reinforcing previous lines of evidence that 
lithium is an important influence on incidence of neurodegeneration. Our work suggests rational 
prioritization for which disorders are likely to be most sensitive to lithium and identifies genes that 
are likely to be useful targets for therapy adjunct to lithium. 
 
Keywords: Lithium, systems biology, affective disorders, neurodegenerative disorders, biochemical 
pathways, biochemical networks 
 
Introduction 
Lithium is typically the first line therapy for bipolar disorder, including associated 
depression as well as mania.1  A comprehensive review of the literature confirms that lithium is 
also effective against unipolar depression with unique anti-suicidal effectiveness, and may also be 
useful against cancer and neurodegenerative disease.2   
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Significant insights have been gained into the biochemical bases of lithium’s action.  The 
lithium-sensitive enzyme glycogen synthase kinase 3-beta (GSK3B)3 inhibits signaling induced 
by Brain-Derived Neurotrophic Factor (BDNF).4  Thus lithium would be expected to enhance 
activity of BDNF.  BDNF may be a key bridge between affective and neurodegenerative disorders, 
since levels of this enzyme have been implicated in depression5, bipolar disorder 6 7, and dementia8.  
Indeed, in animal experiments, lithium was shown to induce brain-derived BDNF. 9 In addition, 
BDNF has been shown to play an important role in survival of adult and developing central neurons 
both in culture and in vivo.10 11 12 13 14  The role of lithium in increasing activity of BDNF plus the 
role of BDNF in survival of neurons support the hypothesis that lithium might have a role to play 
in the treatment of neurodegenerative disease.15   
Other reported research results have supported the potential of lithium for treatment of 
neurodegenerative disease.16 However relevant clinical trials remain to be done.  In the absence of 
clinical trial results, insights may be obtained from comparative studies on bipolar patients who 
have received long-term lithium treatment, and those who have not.  In one such study, in an 
otherwise well-matched cohort of elderly (approximately 70 years old), 5% of those on long-term 
lithium therapy (continuous for the previous five years) were diagnosed with Alzheimer’s disease 
(AD), while 33% of those not receiving consistent lithium therapy were diagnosed with AD.17   
Epidemiological studies on the general population are suggestive.  A recent nationwide 
study in Denmark showed that lithium level in the drinking water was significantly correlated with 
incidence of dementia, with higher lithium levels showing lower levels of dementia.18  A more 
recent epidemiological study in Texas showed a similar specific effect for Alzheimer’s disease.19  
An important feature of the epidemiological studies is that they involve levels of lithium ingestion 
that are many times smaller than those used for bipolar therapy, and are therefore almost certainly 
without significant side effects. 
One neurodegenerative disorder, frontotemporal dementia (FTLD), initially presents with 
behavioral symptoms resembling mania,20 posing a challenge for diagnosis.  A definitive diagnosis 
in the early stage of the disease requires neuroimaging.21  The consensus is that FTLD is invariably 
fatal, with a more rapid progression than Alzheimer’s Disease.22  However, there may be one 
documented apparent exception to the incurability of FTLD, in a case history presented by Monji 
et al.23 In this study a middle-aged man presented manic symptoms that had no apparent origin in 
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early life.  Because imaging revealed abnormalities typical of FTLD, a diagnosis of FTLD was 
made.  However, because the psychiatric symptoms had a pattern like bipolar disease, lithium 
therapy was begun.  In a little under two years the psychiatric symptoms had been completely 
mitigated and new brain images appeared normal.  The authors concluded that the initial diagnosis 
of FTLD was in error.   However, the data presented in the paper were also consistent with the 
hypothesis that the FTLD diagnosis was correct and that the lithium therapy reversed the course 
of the disease. Dr. Monji, first author on the study, confirmed in an email to us that this hypothesis 
was consistent with their data.   
A case history suggests efficacy of lithium for alleviating agitation and psychosis in both 
FTLD and Alzheimer’s disease.24 The efficacy of lithium for FTLD patients is to be tested in a 
recently announced clinical trial,25 although only with respect to relief of the behavioral symptoms 
cited in the above reference over the course of a 12-week trial.  The limited scope of this study is 
a continuation of a line of thought that considers affective and neurodegenerative aspects of FTLD 
as relatively separate26, a line of thought that we question because of the evidence discussed above.    
Dysfunction of autophagy is strongly implicated in neurodegenerative disease.27 28 29 30  
Lithium has been shown to induce autophagy, due to its inhibition of inositol monophosphatase.31  
This is the basis of a pathway for autophagy enhancement, independent of the well-studied effects 
of mTOR on autophagy.32 This additional pathway for autophagy enhancement has led to the 
suggestion of a combined lithium-rapamycin treatment for Huntington’s Disease, with lithium 
inhibiting inositol monophosphatase and rapamycin inhibiting mTOR.33   
The full range of lithium effects on autophagy is complicated,34 as might be expected 
because of lithium’s lack of specificity.  
Because lithium affects many different biological molecules and processes2, it is essential 
to utilize the tools of systems biology35 if a comprehensive understanding of lithium action and its 
prospects for therapy are to be obtained.  Important concepts for organizing biological information 
in a systems context are pathways and networks.  A very useful tool for obtaining data about known 
pathways is the KEGG database.36  An equally useful and complementary tool is the STRING 
database of interacting proteins.37 
In the present paper we investigate further the possible linkages among 1) lithium, 2) 
affective disorders, and 3) neurodegenerative disorders by analyzing the mutual enrichment 
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between the interactomes of lithium-sensitive enzymes, and the KEGG pathways associated with 
affective and neurodegenerative disorders.  
Methods 
Analysis was performed on the interactomes of lithium-sensitive genes, as identified by 
prior literature search2. This search suggested BDNF, BPNT1, DISC1, DIXDC1, FBP1, FBP2, 
GSK3A, GSK3B, inositol monophosphatases (IMPA1, IMPA2, and IMPAD1), INPP1, and PGM1 
as key to understanding the broad biological actions of lithium. The interactomes of these genes 
were extracted from the STRING database (https://string-db.org).  For each key gene, we adjust 
confidence level and order of neighbors (nearest only or next nearest included), so that each set 
contains a few hundred genes. This size is large enough for statistically reliable enrichment 
analysis.  Table 1 shows the minimum confidence level and the maximum order of interaction 
(direct, removed by one, etc.) for each set.  Very similar sets were merged; in particular FBP1 and 
FBP2 were merged into one set, and the inositol monophosphatases were merged into one set. On 
the other hand, GSK3A and GSK3B showed sufficient differences to be considered separately.  
Overall, we consider 10 distinct lithium-sensitive entities. 
Gene Confidence level Order of Neighbor Interactome Size 
BDNF 0.4 1 335 
BPNT1 0.6 2 388 
DISC1 0.8 2 113 
DIXDC1 0.6 2 378 
FBP1 0.9 2 175 
GSK3A 0.4 1 307 
GSK3B 0.4 1 225 
IMPAD 0.9 2 504 
INPP1 0.7 2 228 
PGM1 0.4 1 176 
Table 3.1 Interactome parameters and sizes for lithium-sensitive genes.  
Disease Association 
We used the R-package KEGGgraph38 39 to identify the genes associated with the pathways 
of interest.  For one condition, bipolar disorder, there was no annotated pathway in the KEGG 
database. In lieu of an annotated pathway, we used the list of bipolar-related genes compiled by 
Nurnberger et al40.  
Empirical p-value calculation 
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The fundamental question we address is whether there is significant overlap or mutual 
enrichment between the interactomes of lithium-sensitive genes and the pathways or gene sets 
implicated in affective and/or neurodegenerative disorders.  
For each of the 10 lithium sets, an ensemble of 1000 null sets are generated by random 
selection from the human genome. Each null set is the same size as the corresponding lithium set. 
Then we used the R-package STRINGdb41 to perform KEGG pathway enrichment analysis.  This 
operation is a particular example of the powerful technique of gene-annotation enrichment 
analysis.42 In gene-annotation enrichment analysis a test list of genes (often derived from gene 
expression experiments) is compared to an organized database of gene annotations, often referred 
to as a gene ontology43, an array of gene lists corresponding to different biological functions, 
molecular functions, or locations in the cell.  The output of the gene-annotation enrichment 
analysis is expressed as the likelihood that the list overlaps could have occurred by chance (p-
value).  A very low p-value implies that the degree of overlap is highly significant statistically and 
very likely is significant biologically. In our study the gene lists we are comparing are the 
interactomes of lithium sensitive enzymes on the one hand, and KEGG pathways or otherwise 
derived lists associated with neural disease on the other hand.  For each KEGG term retrieved, a 
null distribution of uncorrected p-value is generated by the 1000 null sets.  This gives us a measure 
of the false discovery rate, since any overlap between the null sets and the KEGG pathways is 
purely accidentally. Then the fraction of null set uncorrected p-values smaller than or equal to the 
lithium-sensitive set uncorrected p-value would be the empirical p-value. For a detailed discussion 
of empirical p-value determination see Ge et al44.  
Key Gene Prediction 
We predict key genes by counting how many times a gene appears in the cross section of 
interactomes and pathways associated with a particular disease. Then the counts are normalized 
by number of pathways associated with each disease. In this way, we predict which genes might 
be robust in disease-related pathways. Then, the genes are scored by the sum of mean counts over 
all diseases. A higher ranking indicates a gene would be associated with an important factor in 





Figure 3.1. Heatmap for Lithium-sensitive enzyme interactome enrichment in disease-related 
pathways. The empirical enrichment p-value was calculated for each set of disease-associated genes. a) and 
b) are disorders where lithium treatment has proved to be effective and both show high enrichment. c) and d) 
are diseases where the effect of lithium treatment is unknown. c) shows relatively low enrichment while d) 
shows high enrichment.  
Figure 3.1 shows a few examples of mutual lithium interactome enrichment with specific 
disease pathways, represented by heatmaps. Each area on the heatmap is a color-coded 
representation of the degree of mutual enrichment between the genes in the interactome of the 
indicated lithium sensitive enzyme and the genes in the indicated pathway.  The darker the shade, 
the more significant the mutual enrichment of the interactome-pathway combination is.  Fig.3.1 a) 
and b) shows two diseases where lithium treatments have been effective, and both show very strong 
enrichment. Fig.3.1 c) and d) shows two diseases where the effect of lithium treatment has not 
been explored. Parkinson’s disease, Fig.1 c), shows low enrichment while FTLD, Fig.3.1 d), shows 
high enrichment.  We infer that FTLD is a more likely disease target for lithium treatment than 
Parkinson’s Disease.  A spreadsheet providing p-values for the mutual enrichment of the lithium 
sensitive interactomes and the relevant pathways for all 112 diseases studied are provided in 
supplementary material. 
For each of the 112 diseases considered we computed the geometric mean of the inverse 
of the p-values for each interactome/pathway enrichment and propose this as a “lithium sensitivity 
index” for the disease. The lithium sensitivity index is just the reciprocal of the mean p-value for 
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each of the mutual enrichments between lithium-sensitive interactomes and the relevant pathways, 
where the mean p-value is: 
                 pmean=1/((1/p1)x(1/p2)x(1/p3)x…….x(1/pn))1/n                 Equation (3.1) 
We note that the individual p-values vary by several orders of magnitude.  The method of 
averaging in Equation (3.1) ensures that both strong and weak enrichments contribute significant 
weight to the mean.  Note also that our method is bounded at the low end of p-values by the number 
of null samples it is reasonable to compute, given compute time constraints.  For ten thousand null 
sets as used in this paper, the lowest p-values are not numbers but the expression <1E-4, which 
means that the degree of mutual enrichment was greater for the test set than for all ten thousand of 
the null sets.  For computing the inverse of the lowest p-values, we set the inverse at 1E+4.   
Table 3.2 shows the top 34 ranked diseases out of the 112.  Note that two diseases for 
which lithium is known to be effective therapy, bipolar disorder and major depression disorder, 
rank high, 9 and 29 respectively.   Other notable diseases shown in Table 3.2 include Alzheimer's 
(20 out of 112), for which there is epidemiological evidence17 above, FTLD (30 out of 112) for 
which there is evidence via case history23, and schizophrenia (22 out of 112) for which there is 
some evidence of efficacy as an adjunct to antipsychotics.45 Scores for all 112 diseases are 






Disease Sensitivity index Mean p-value 
Dravet syndrome 1718.943899 .0006 
HTLV1-Associated Myelopathy (HAM) 626.8531541 .0016 
Congenital pain insensitivity with anhidrosis 466.9837537 .0021 
Hemorrhagic destruction of the brain, subependymal 
calcification, and cataracts 
418.143026 .0024 
Rasmussen encephalitis 293.1481892 .0034 
Lattice corneal dystrophies (LCD) 263.6451883 .0038 
Subependymal giant cell astrocytoma 246.0470815 .0041 
Bipolar Disorder 239.2876 .0042 
Familial episodic pain syndrome (FEPS) 231.5937968 .0043 
Familial exudative vitreoretinopathy (FEVR) 205.3474156 .0049 
Focal dermal hypoplasia 205.3474156 .0049 
Choroid plexus papilloma 198.0197413 .0051 
Juvenile-onset dystonia 183.6715435 .0054 
Prion diseases 175.0031999 .0057 
Axenfeld-Rieger syndrome (ARS) 169.1174332 .0059 
Congenital stromal corneal dystrophy (CSCD) 169.1174332 .0059 
Ring dermoid of cornea 169.1174332 .0059 
Stapes ankylosis with broad thumb and toes 169.1174332 .0059 
Benign familial neonatal and infantile epilepsies 153.4488999 .0065 
Alzheimer's disease 148.6362283 .0067 
Neurosis 132.0111986 .0076 
Schizophrenia 132.0111986 .0076 
Pituitary adenomas 123.9488444 .0081 
Febrile seizures 108.3195689 .0093 
Episodic ataxias 104.5457633 .0095 
Familial or sporadic hemiplegic migraine 104.5457633 .0095 
Cerebral amyloid angiopathy (CAA) 89.36992044 .0112 
Major depressive disorder 89.36992044 .0112 
Epileptic encephalopathy with continuous spike-waves 
during slow-wave sleep 
87.85098473 .0114 
Frontotemporal lobar degeneration (FTLD) 75.82609324 .0132 
Cerebral palsy 72.92882566 .0137 
Generalized epilepsy and paroxysmal dyskinesia 
(GEPD) 
69.3705138 .0144 
Amyotrophic lateral sclerosis (ALS) 67.25422275 .0149 
Fleck corneal dystrophy (FCD) 63.08690002 .0158 
Table 3.2. Top 34 neuron-related disease by lithium sensitivity.  
As a control on our methods, we compared the statistical distribution of scores for neural 
disease with corresponding scores for metabolic pathways (also from KEGG), and with random 
gene sets (null sets).  This comparison is shown in box plots in Figure 3.2. As expected the scores 
for the null sets are quite low, collapsing into a range between 1 and 2.05.  The scores for the 
metabolic pathways are also low, reflecting fact that lithium has not been found to be major 
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modulator of metabolism.  Just two metabolic pathways account for the height of the upward 
extension of the metabolic box plot, carbohydrate metabolism and nucleotide metabolism.  On the 
other hand, the scores for neural diseases are quite high.  These scores, together with large numbers 
of cell, animal, and epidemiological studies suggesting lithium may play a role in ameliorating this 
class of disease, suggest moving forward into clinical trials for selected affective and 
neurodegenerative disorders.  Even in studies in which lithium is not the primary variable, 
environmental lithium should be measured and correlated with outcomes or used as an 
experimental variable, because of the possibility that lithium and another drug may be synergistic. 
For example, lithium and rapamycin stimulate autophagy by independent pathways, leading to a 
suggestion that they might be a promising combination therapy for Huntington’s disease.46  
 
 
Figure 3.2 Log10 of sensitivity index of lithium-sensitive interactome for null sets, metabolic 







































Schizophrenia Bipolar AD ALS FTLD Prion MDD Sum 
MAPK3 0 0 4 0 1.33 4 4 13.33 
APP 0 0 6 0 0 0 6 12 
TP53 0 0 0 5 2.5 0 0 7.5 
RAC1 0 0 0 4 2 0 0 6 
PSEN1 0 0 4 0 2 0 0 6 
PLCB3 0 0 3 0 0 0 3 6 
PLCB2 0 0 3 0 0 0 3 6 
PLCB1 0 0 3 0 0 0 3 6 
PPP3CC 0 0 3 3 0 0 0 6 
PRKACB 0 0 0 0 0 3 3 6 
ITPR1 0 0 3 0 0 0 3 6 
PPP3CA 0 0 3 3 0 0 0 6 
PRKACG 0 0 0 0 0 3 3 6 
NOS1 0 0 3 3 0 0 0 6 
PLCB4 0 0 3 0 0 0 3 6 
PRKACA 0 0 0 0 0 3 3 6 
CYCS 0 0 3 3 0 0 0 6 
HTR2A 1 2 0 0 0 0 2 5 
NOTCH1 0 0 0 0 0 5 0 5 
GAPDH 0 0 5 0 0 0 0 5 
MAP2K1 0 0 0 0 0.67 2 2 4.67 
BAX 0 0 0 2 0.67 2 0 4.67 
GRM1 1.5 3 0 0 0 0 0 4.5 
TNF 0 0 2 2 0 0 0 4 
GNAQ 0 0 2 0 0 0 2 4 
GNG2 0 2 0 0 0 0 2 4 
ITPR3 0 0 2 0 0 0 2 4 
CDK5 0 0 4 0 0 0 0 4 
FYN 0 0 0 0 0 4 0 4 
IL1B 0 0 2 0 0 2 0 4 
ITPR2 0 0 2 0 0 0 2 4 
PRKCA 0 0 0 0 0 0 4 4 
PPP3CB 0 0 2 2 0 0 0 4 
Table 3.3.  Gene counts normalized by pathway number for genes appearing at intersection of 




In addition to pathways we examined our results to identify specific genes within the 
lithium sensitive interactomes that may be important in modulating lithium effect on disease are 
useful to identify.  Table 3.3 indicates the genes that occur with the greatest frequency at the 
intersection of the lithium-sensitive interactomes and pathways associated with selected neural 
diseases.  The complete tally for all 112 diseases considered in this study is provided in 
supplementary material.  We suggest that genes that appear prominently at the intersection of 
lithium sensitivity and neural disease pathways, and their promoter regions, should receive 
attention as possible sites of important mutations affecting lithium response to neural disease, and 
possibly as targets for drugs more specific than lithium.  This is in addition to the ten lithium-
sensitive genes that were used as a starting point for this study, based on their previous mentions 
in the literature.  
The genes in Table 3.3 are ranked by total number of appearance across the diseases. The 
high rank indicates that a gene might be 1) found associated with multiple diseases or 2) associated 
with multiple interactomes for a particular disease-associated pathway. For the former case, the 
gene might indicate similar mechanisms for the multiple diseases. For the latter case, the gene 
would be a promising target in treatment of that particular disease.  
For example, Table 3.3 have shown that MAPK3 is a shared gene by Alzheimer's Disease 
(AD), Prion, Major Depressive Disorders (MDD), and Frontotemporal lobar degeneration (FTLD), 
indicating that these diseases might have some shared mechanism. MAPK3 appeared in 4 
interactome-pathway cross-sections in AD, Prion and MDD, and on average associated with 1.33 
interactome-pathway cross-section in FTLD.  MAPK3 is an essential component of the MAP 
signal transduction pathway that carries signals from cell surface to the nucleus.  In analysis of 
normal as compared to AD brain tissue, MAPK3 is one of a small number of genes found to have 
alternative promoter usage and splicing.47   
Another prominent gene in Table 3.3 is APP (amyloid precursor protein), which gives a 
strong signal in both AD (Alzheimer’s Disease) and MDD (Major Depressive Disorder).  
Published studies implicate specific mutations in APP in incidence of AD 48, and implicate amyloid 
beta, the cleavage product of APP, in incidence of MDD.49   Lithium has well established efficacy 
in the treatment of MDD,50 and regulates the production of amyloid beta.51 Taken together these 
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findings suggest that influence of lithium on APP may be a common mode of action of lithium 
effect on both Alzheimer’s disease and major depressive disorder.  
Summary and Discussion 
We have conducted a pathway and network analysis of the role of lithium in 122 
neurodegenerative and affective disorders.   We have found that for the large majority of such 
disorders, there is high mutual enrichment between the interactomes of lithium-sensitive enzymes 
and the pathways associated with those diseases, indicating that lithium is very likely to affect the 
course of the disease.  We have also identified specific genes that exist frequently at the 
intersection of lithium-sensitive interactomes and neural disease pathways, suggesting these genes 
as possible targets for more specific drugs than lithium.   
We hope that the results described in this paper and more detailed supplementary material 
will contribute to prioritizing and designing clinical trials of lithium for neural disease.  To provide 
context for such prioritization and design, it is essential to take into account the ways in which 
lithium is unique, both as a pharmaceutical and as an ion that is ubiquitous in the environment, and 
therefore ubiquitous in the water and food we ingest2: 
1. Unlike other ions, lithium is not regulated by selective membrane transport processes.  
Therefore, lithium concentration in both extracellular and intracellular compartments, 
rather than being roughly constant, is roughly proportional to lithium ingestion. 
2. Unlike other pharmaceuticals, lithium is wildly nonselective in its biochemical effects.  The 
major underlying mechanism for the lack of selectivity is lithium’s general propensity to 
inhibit the many enzymes that have magnesium as a cofactor. 
3. Unlike other pharmaceuticals, lithium is an essential nutrient.  The question with lithium 
is not whether it should be ingested or not, but rather how much.  Extreme lithium 
deprivation results in failure to thrive, while too much lithium is toxic.  
In the light of all these factors, we suggest that the correct question to ask with respect to 
lithium and a particular disease is not, “Should lithium be administered for this particular disease?” 
but rather, “What is the optimum blood level of lithium for this individual, given his or her disease 
history, status, and genetic propensities?”  Unlike other pharmaceuticals that are far more specific 
and inhibit or activate one or a small number of genes, the model for lithium action is that it alters 
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the balance between a large number of interacting processes and pathways.  Thus, a dose-response 
curve for lithium is likely to be highly nonlinear and not always monotonic.  
There are just a few well-established markers for optimum concentrations. For a patient 
with a reliable diagnosis of bipolar disorder a common target would be 0.8-1 mM.  Significantly 
higher concentrations will result in acute toxicity, while significantly lower will result in loss of 
effectiveness.  Epidemiological studies on bipolar patients who are, and are not, on lithium therapy 
suggest that this level also protects against Alzheimer’s disease.  However, this level has some 
side effects when sustained for years or decades, namely an increased risk of kidney damage and 
lowered thyroid activity.  Thus, for other conditions one would like to find lower effective 
concentrations; indeed one would like to do that for bipolar disorder as well, perhaps by combining 
lithium with other mood stabilizers that act in a synergistic fashion, enabling the lithium dose to 
be reduced. 
At the other end of the dosage scale, epidemiological evidence is compelling that 
geographical variations in concentration of lithium in the drinking water are correlated with 
incidence of Alzheimer’s; the lower the lithium the higher the incidence of mania.  It thus seems 
that for Alzheimer’s, an optimum level of blood lithium would be higher than the naturally 
occurring range, but perhaps lower than the therapeutic dose for bipolar disorder in order to 
minimize possible side effects of the bipolar therapeutic dose. 
Another important marker is provided by a study showing that over a four-year period a 
lithium level of .25-.4 mM of lithium (1/3 to 1/2 of the bipolar therapeutic dose) did not incur any 
renal damage52.  This study suggests that clinical studies exploring low to medium-dose lithium 
could be undertaken with relatively minimal concerns for side effects. 
One of the authors (EJ) is an elderly person (79) and has found the evidence cited above 
sufficiently compelling that he self-administers lithium calibrated to a blood level of .3-.4 mM, in 
order to reduce the pace of age-related neurodegeneration.  His outcome, however important it 
may be to him personally, has no statistical significance.  We need a clinical study involving many 
subjects addressing the same question. 
In general, it seems clear that whatever other studies are undertaken with respect to 
affective and neurodegenerative disorders, lithium blood levels should be monitored, since even 
geographical variations may have significant effects.  The cost of adding lithium level to the 
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routine blood tests is minimal, especially compared to the potential benefits.  Beyond that, multiple 
studies should be undertaken in which low- to moderate-level lithium supplements are 
administered, since these are likely to be safe (although of course side effects should be 
monitored). 
Perhaps our results, especially as scored in Table 1 and combined with other 
considerations, might help to focus on which neurodegenerative diseases might be most useful to 
consider for lithium therapy.  Other considerations might be: 1) whether the disease impacts a large 
number of people, so that alleviating the condition would relieve much suffering, 2) the age at 
which the condition strikes, considering that the impact on individual, family, and others may be 
more if the disease strikes at a younger age, 3) the mortality rate, and 4) how rapidly the disease 
progresses, since the more rapidly progressing the disease the more rapidly meaningful statistics 
may be gathered from an intervention trial.  
Many conditions that score highly in Table 1 might be usefully considered.  One condition 
that looms large to us, because of the loss of a person close to us at the age of 46, is FTLD.  The 
mean p-value for FTLD pathway mutual enrichment with lithium-sensitive interactomes is .0132, 
which is highly significant. While not as common as Alzheimer’s, FTLD is not rare.  Estimated 
lifetime risk is 1/742, so many millions of people each year die of FTLD.53  The ratio of official 
incidence to mortality is 0.97; it is generally accepted to be 100% lethal. Life expectancy after 
diagnosis depends on the variant, but ranges from 3 to 9 years, so progression is much more rapid 
than Alzheimer’s, and permits meaningful statistical analysis of any clinical trial in a relatively 
short time.  Age of onset is most typically middle- to late middle-age when the individual is still 
employed and a crucial part of nuclear and extended family, in contrast to typically later onset of 
Alzheimer’s. We have noted earlier in this paper that the initial symptoms of FTLD are sufficiently 
similar to mania (which is treated successfully with lithium) to sometimes lead to confusing 
diagnoses, which may suggest a common underlying biochemistry.  
We will be happy to collaborate on further specific pathway or network analysis relevant 
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Abstract 
Lithium has many widely varying biochemical and phenomenological effects, suggesting 
that a systems biology approach is required to understand its action.  Multiple lines of evidence 
point to lithium as a significant factor in development of cancer, showing that understanding 
lithium action is of high importance.  In this paper we undertake first steps towards a systems 
approach by analyzing mutual enrichment between the interactomes of lithium-sensitive enzymes 
and the pathways associated with cancer.  This work integrates information from two important 
databases, STRING and KEGG pathways.  We find that for the majority of cancer pathways the 
mutual enrichment is many times greater than chance, reinforcing previous lines of evidence that 
lithium is an important influence on cancer.   
Keywords: Lithium, systems biology, biochemical pathways, biochemical networks 
Introduction 
Clinical and Epidemiological Context for Lithium and Cancer  
By far the most common medical use of lithium is as a first line therapy for bipolar disorder, 
including associated depression as well as mania.1  A comprehensive review of the literature 
confirms that lithium is also effective against unipolar depression with unique anti-suicidal 
effectiveness, and may also be useful against cancer and neurodegenerative disease.2   
One line of evidence for the possible use of lithium as an anticancer agent is 
epidemiological.  A retrospective study showing that psychiatric patients undergoing lithium 
therapy for bipolar disorder had a much lower incidence of cancer than a matched group not 
receiving lithium therapy.3 More recent studies of similar design, one conducted nationwide across 
Sweden, and another across Taiwan, achieved the same result.4 5 On the other hand another 
nationwide study, this time from Denmark, showed no correlation of lithium with colorectal 
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adenocarcinoma.6 On closer look, the Denmark study does not contradict the Swedish study.  The 
Swedish study also found that for the entire population lithium was not correlated with cancer 
incidence, but in addition found that bipolar individuals not treated with lithium had a higher 
incidence of cancer than the general population.  Lithium-treated bipolar patients, on the other 
hand, had essentially the same cancer incidence as the general population.  
One piece of experimental evidence for lithium’s potential as a cancer therapeutic modality 
is that it was observed to inhibit prostate tumor growth,7 presumably through its ability to inhibit 
GSK3. A detailed study of molecular mechanisms by which lithium inhibition of GSK3-beta 
inhibits proliferation of prostate tumor cells in culture was presented by Sun et al.8 The work was 
subsequently extended to an animal model.9  A clinical trial for the effect of lithium coupled with 
prostatectomy on men has been conducted but as of this writing results have not yet been 
published.10  
With respect to other cancers, lithium has been found to be lethal to neuroblastoma cells 
but not to normal nerve cells.11  The experimentally determined effective dose was 12 mM, a level 
which would be lethal if achieved systemically in a human or model organism but perhaps could 
be induced locally.  A similar effect was found in ovarian cancer cells,12 although a subsequent 
similar study on ovarian cancer cells suggests only a more modest benefit.13 It is not clear from 
our reading of the two ovarian cancer papers why the results are significantly different from each 
other. 
With respect to colorectal cancer, one study suggests that lithium inhibits proliferation of 
a colorectal cancer cell line.14 Another study on colon cancer cells showed that lithium specifically 
induced a reversal of the epithelial-to-mesenchymal transition characteristic of the cancer cells.15  
Two studies with relatively small sample size suggested a possible link between lithium 
and tumors of the upper urinary tract.16 17 However a large-scale study involving all urinary tract 
cancers in Denmark over a multi-year period found no correlation with lithium use.18 
Because lithium therapy is systemic rather than topical or local, it follows that lithium 
might inhibit metastasis.  Evidence that this is the case for colon cancer comes from observation 
of inhibition of metastasis-inducing factors by lithium and by observation on reduced metastasis 
in model animals given lithium therapy.19 
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Autophagy is a key cellular process in the inhibition of cancer.20  Lithium has been shown 
to induce autophagy, due to its inhibition of inositol monophosphatase.21  The full range of lithium 
effects on autophagy is complicated,22 as might be expected because of lithium’s lack of 
specificity.2   
Because of the promising indications as cited above, lithium has been suggested as one of 
a number of drugs commonly used for other reasons, to be repurposed for cancer.23 
Biochemical Context for Lithium and Cancer 
Much of lithium’s biochemical action may be summarized by noting that it inhibits 
enzymes that have magnesium as a co-factor.2 There are many published examples of such 
competition. Lithium appears to inhibit β-adrenergic and muscarinic receptor coupling to G 
proteins by competing with magnesium, which facilitates such coupling. 24 25 26 27 28  A particularly 
important example is substitution of a lithium ion for a magnesium ion acting as a cofactor in 
inositol monophosphatase, mentioned earlier in this paper.  In this protein the binding site for 
lithium is not revealed in crystallography nor in solution NMR but can be identified in magic angle 
spinning solid state NMR, which is more suitable for systems with large internal motion.29 Another 
target of lithium, also a magnesium-dependent phosphatase and with relevance to neural effects, 
is bisphosphate 3-prime-nucleotidase (BPNT1).30 31  These findings are consistent with a 
hypothesis that lithium inhibits at least some magnesium-dependent enzymes by displacing 
magnesium from its binding site thereby reducing the structural stability and lowering activity of 
the enzyme.   
One mode of action with many consequences is lithium inhibition of glycogen synthase 
kinase 3 beta (GSK3B), initially shown in vitro and in intact cells,32 and in the context of 
embryonic development.33 It was later shown that lithium exerted its inhibitory effect on GSK3B 
by competing with magnesium for an essential binding site.34  There are two closely related forms 
of GSK3, termed alpha (GSK3A) and beta (GSK3B), which are equivalently inhibited by 
lithium.35 The two forms of GSK3 have substantial functional redundancy.36  However some of 
their physiological properties are different, as demonstrated by the fact that GSK3B knockout mice 
are not viable,37 but GSK3A knockout mice survive.38 The very widespread nature of  GSK3B 
effects is related to the large number of transcription factors that it regulates.39  It functionally 
modulates cellular threshold for apoptosis,40 it is central to mediating mitochondrial response to 
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stress;41 it facilitates immune responses by enabling the nuclear export of NF-ATc;42 it regulates 
inflammation;43 it regulates cardiac hypertrophy and development,44 to name just a few.  Based 
on microarray studies of brain cells in animals, lithium alters gene expression patterns 
significantly,45 to be expected due to the large number of transcription factors regulated by 
GSK3B.  Mice heterozygous for GSK3B exhibit similar behavioral traits to wild type littermates 
treated with 1mM lithium (a concentration that inhibits about 25% of GSK3 activity, in line with 
1 of the 4 alleles of GSK3 inactivated in the GSK3B heterozygous mice)46 
In addition to inhibiting the activity of GSK3B, lithium also inhibits its transcription.47  Of 
all kinases, GSK3 appears to have the largest number of known substrates, over 100 known48 and 
about 500 predicted by theory based on scanning and interpreting relevant motif sequences in the 
human genome.49 Lithium will thus to some extent modulate activity along all pathways containing 
the hundreds of GSK3 substrates. So far, to our knowledge there are no published counterexamples 
to the hypothesis that lithium will exert an inhibitory effect on all proteins with essential 
magnesium binding sites, of which there are estimated to be over three thousand.50 
A second major widespread effect of lithium is as a cofactor with magnesium in interacting 
with phosphate groups.  The primary energy source for cells and the substrate for phosphorylating 
enzymes is not bare ATP, but rather magnesium-associated ATP (MgATP).51  NMR studies show 
that lithium associates with MgATP.52  Based on this admittedly small amount of data, we 
hypothesize that lithium associates with all magnesium-phosphate complexes and will thus 
modulate to some extent all phosphorylation reactions and all ATP-splitting processes.  This is a 
reasonable interpretation of early work by Willis and Fang, in which lithium was found to increase 
the activity of the sodium-potassium pump without itself being transported significantly.53  We 
have noted earlier in this paper the inhibitory effect of lithium on GSK3 by the mechanism of 
competing with Mg.  Here we note that lithium also inhibits the activity of GSK3 by a second 
method, that is, by increasing phosphorylation.54  Depending on context of relevant protein-protein 
interactions, lithium’s effect on phosphorylation of a particular protein may be to either increase 
it or decrease it.  For example, lithium decreases phosphorylation of tau-protein, presumably 
because it inhibits GSK3B, which is implicated in the phosphorylation of the tau-protein.55 
Because lithium affects many different biological molecules and processes2, it is essential 
to utilize the tools of systems biology56 if a comprehensive understanding of lithium action and its 
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prospects for therapy are to be obtained.  Important concepts for organizing biological information 
in a systems context are pathways and networks.  A very useful tool for obtaining data about known 
pathways is the KEGG database.57  An equally useful and complementary tool is the STRING 
database of interacting proteins.58 
In the present paper we investigate further the possible linkages among 1) lithium, 2) 
affective disorders, and 3) neurodegenerative disorders by analyzing the mutual enrichment 
between STRING-derived interactomes of lithium-sensitive enzymes, and the KEGG pathways 
associated with cancer. 
Methods 
Analysis was performed on the interactomes of lithium-sensitive genes, as identified by 
prior literature search2. This search suggested BDNF, BPNT1, DISC1, DIXDC1, FBP1, FBP2, 
GSK3A, GSK3B, inositol monophosphatases (IMPA1, IMPA2, and IMPAD1), INPP1, and PGM1 
as key to understanding the broad biological actions of lithium. The interactomes of these genes 
were extracted from the STRING database (https://string-db.org).  For each key gene, we adjust 
confidence level and order of neighbors (nearest only or next nearest included), so that each set 
contains a few hundred genes.  This size is large enough for statistically reliable enrichment 
analysis.  Very similar sets were merged; in particular FBP1 and FBP2 were merged into one set, 
and the inositol monophosphatases were merged into one set. On the other hand, GSK3A and 
GSK3B showed sufficient differences to be considered separately.  Overall, we consider 10 distinct 
lithium-sensitive entities. 
Disease Association 
We used the R-package KEGGgraph59 60 to identify the genes associated with the pathways 
of interest.   
 
 P-value calculation 
The fundamental question we address is whether there is significant overlap or mutual 
enrichment between the interactomes of lithium-sensitive genes and the pathways or gene sets 
implicated in various cancers.  
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For each of the 10 lithium sets, an ensemble of 1000 null sets are generated by random 
selection from the human genome. Each null set is the same size as the corresponding lithium set. 
Then we used the R-package STRINGdb61 to perform KEGG pathway enrichment analysis.  This 
operation is a particular example of the powerful technique of gene-annotation enrichment 
analysis.62 In gene-annotation enrichment analysis a test list of genes (often derived from gene 
expression experiments) is compared to an organized database of gene annotations, often referred 
to as a gene ontology63, an array of gene lists corresponding to different biological functions, 
molecular functions, or locations in the cell.  The output of the gene-annotation enrichment 
analysis is expressed as the likelihood that the list overlaps could have occurred by chance (p-
value).  A very low p-value implies that the degree of overlap is highly significant statistically and 
very likely is significant biologically. In our study the gene lists we are comparing are the 
interactomes of lithium sensitive enzymes on the one hand, and KEGG pathways and Kegg 
pathways associated with cancer on the other hand.  For each KEGG term retrieved, a null 
distribution of uncorrected p-value is generated by the 1000 null sets.  This gives us a measure of 
the false discovery rate, since any overlap between the null sets and the KEGG pathways is purely 
accidentally. Then the fraction of null set uncorrected p-values smaller than or equal to the lithium-
sensitive set uncorrected p-value would be the empirical p-value. For a detailed discussion of 
empirical p-value determination see Ge et al64.  
 
Key Gene Prediction 
We predict key genes by counting how many times a gene appears in the cross section of 
interactomes and pathways associated with a particular disease. In this way, we predict which 
genes might be most important in disease-related pathways. Then, the genes are scored by the sum 
of mean counts over all diseases. A higher ranking indicates a gene would be associated with an 
important factor in many diseases.  
Results 
Figure 4.1 shows mutual lithium interactome enrichment with specific cancer pathways, 
represented by heatmaps. Each area on the heatmap is a color-coded representation of the degree 
of mutual enrichment between the genes in the interactome of the indicated lithium sensitive 
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enzyme and the genes in the indicated pathway.  The darker the shade, the more significant the 
mutual enrichment of the interactome-pathway combination is. The light areas on the heatmap 
represent situations where a lithium-sensitive interactome has little or no mutual enrichment with 
a cancer pathway.  The dark areas, deep orange and red, represent situations where enrichment is 
very strong—far greater than could be expected by chance. Three genes stand out as being not 
strongly connected to cancer pathways: BPNT1, DISC1, and PGM1. Of the cancer pathways, 
breast cancer stands out as being not likely to be strongly influenced by lithium levels.  For the 
remainder of the genes and the remainder of the cancers, the relationship between the lithium-
sensitive interactome and the cancer phenome is strong. 
For each of the cancer-associated pathways we wished to compute a single number 
representing the relative likely sensitivity of the disease to lithium, in order to contribute to 
prioritizing which diseases are most likely to benefit from clinical trials with lithium.  There is a 
significant literature on combining p-values,65 with choices among methods depending on the 
detailed structure of the data.  We adopt a relatively simple approach, which is to compute the 
geometric mean of the individual p-values for each pathway-interactome mutual enrichment value.    
pmean=(p1 x p2 x p3 x……pn)1/n                 Equation (1) 
The method of averaging in Equation (1) ensures that both strong and weak enrichments 
contribute significant weight to the mean.  Note that all of the p-values that go into Equation (1) 
are corrected for false discovery rate by random resampling.  Thus, no further false discovery rate 
correction is necessary for computing pmean. Note also that our method is bounded at the low end 
of p-values by the number of null samples it is reasonable to compute, given compute time 
constraints.  For one thousand null sets as used in this paper, the computed p-value will be zero 
when none of the thousand null sets shows the degree of enrichment of the test sets.  For purposes 




Figure 4.1. Visual representation of mutual enrichment patterns between cancer-associated 
pathways and the interactomes of lithium-sensitive gene products. Calibration of p-value vs. color is 
indicated by a vertical scale to the right of the heat map. Red or dark orange indicates very strong enrichment 
while lighter color indicates weak or, if white, no enrichment. Three genes stand out as being not strongly 
connected to cancer pathways: BPNT1, DISC1, and PGM1. Of the cancer pathways, breast cancer stands out 
as being not likely to be strongly influenced by lithium levels. For the remainder of the genes and the 












































Cancer-related KEGG pathway pmean 1/pmean 
Colorectal_cancer 0.00049903 2003.89209 
Pancreatic_cancer 0.00053973 1852.76828 
Proteoglycans_in_cancer 0.00054323 1840.83131 
Renal_cell_carcinoma 0.00056283 1776.72794 
Pathways_in_cancer 0.00056569 1767.76501 
Chronic_myeloid_leukemia 0.00085134 1174.61894 
Non-small_cell_lung_cancer 0.00090896 1100.15513 
Endometrial_cancer 0.00091244 1095.95823 
Prostate_cancer 0.00091481 1093.12212 
MicroRNAs_in_cancer 0.00093106 1074.04618 
Melanoma 0.00093303 1071.77346 
Viral_carcinogenesis 0.00099762 1002.38273 
Glioma 0.00122264 817.904951 
Acute_myeloid_leukemia 0.00125638 795.934615 
Bladder_cancer 0.00150566 664.158631 
Small_cell_lung_cancer 0.00352993 283.291551 
Thyroid_cancer 0.00567253 176.288152 
Basal_cell_carcinoma 0.03711938 26.9401078 
Chemical_carcinogenesis 0.05277248 18.9492716 
Transcriptional_misregulation_in_cancer 0.14953148 6.68755483 
Central_carbon_metabolism_in_cancer 1 1 
Choline_metabolism_in_cancer 1 1 
Breast_cancer 1 1 
Table 4.1. Rank order of significance of enrichment between lithium-sensitive interactomes and 
KEGG cancer-associated pathways. It is seen that for the great majority of pathways the mutual enrichment 
is very significant, with p-values significantly below .01. Breast cancer is unusual; it appears there is no 
enrichment beyond chance. The table also displays a “lithium sensitivity index”, which is 1/p mean  
Table 4.1 shows in rank order the significance of enrichment between lithium-sensitive 
interactomes and KEGG cancer-associated pathways. It is seen that for the great majority of 
pathways the mutual enrichment is very significant, with p-values significantly below .01. Breast 
cancer is unusual; it appears there is no enrichment beyond chance.  The table also displays a 
“lithium sensitivity index”, which is 1/pmean 
We should note that sensitivity to lithium does not necessarily imply a beneficial 
sensitivity. There are some indications for some cancers that lithium might be beneficial, as 
described in the Introduction section of this paper, but because of the complexity of the feedback 
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relationships in these pathways, a complicated relationship between lithium ingestion and cancer 
incidence is very possible.  
 
Figure 4.2. This figure visualizes the strength of the projected lithium influence on cancer 
pathways. The logarithms of the lithium sensitivity indices (1/p mean) are shown in boxplot format together 
with the corresponding results when the lithium interactomes are replaced with random gene sets. Essentially 
this figure shows the signal-to-noise ratio of our results and demonstrates conclusively that lithium ingestion 
is overwhelmingly likely to modulate the incidence of a wide range of cancers.  
Figure 4.2 visualizes the strength of the projected lithium influence on cancer pathways.  
In this figure the logarithms of the lithium sensitivity indices (1/pmean) are shown in boxplot format 





































gene sets.  Essentially this figure shows the signal-to-noise ratio of our results and suggests that 
lithium ingestion is overwhelmingly likely to influence the incidence of a wide range of cancers.   
Summary and Discussion 
We have conducted a pathway and network analysis exploring the role of lithium in 
multiple cancers.   The results show that for the large majority of such cancers, there is high mutual 
enrichment between the interactomes of lithium-sensitive enzymes and the pathways associated 
with those diseases, indicating that lithium is very likely to affect the incidence and course of the 
disease.  Our results are consistent with a variety of lines of evidence from both epidemiology and 
from experiment, cited in the Introduction section of this paper, suggesting possible influence of 
lithium on the incidence and progression of cancer. 
We hope that the results described in this paper will contribute to prioritizing and designing 
clinical trials of lithium for cancer.  To provide context for such prioritization and design, it is 
essential to take into account the ways in which lithium is unique, both as a pharmaceutical and as 
an ion that is ubiquitous in the environment, and therefore ubiquitous in the water and food we 
ingest2: 
1. Unlike other ions, lithium is not regulated by selective membrane transport processes. 
Therefore, lithium concentration in both extracellular and intracellular compartments, 
rather than being roughly constant, is roughly proportional to lithium ingestion. 
2. Unlike other pharmaceuticals, lithium is wildly nonselective in its biochemical effects. 
The major underlying mechanism for the lack of selectivity is lithium’s general 
propensity to inhibit the many enzymes that have magnesium as a cofactor. 
3. Unlike other pharmaceuticals, lithium is an essential nutrient.  The question with 
lithium is not whether it should be ingested or not, but rather how much.  Extreme 
lithium deprivation results in failure to thrive, while too much lithium is toxic.  
In the light of all these factors, we suggest that the correct question to ask with respect to 
lithium and a particular disease is not, “Should lithium be administered for this particular disease?” 
but rather, “What is the optimum blood level of lithium for this individual, given his or her disease 
history, status, genetic propensities, and other medications?” Unlike other pharmaceuticals that are 
far more specific and inhibit or activate one gene or a small number of genes, the model for lithium 
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action is that it alters the balance between a large number of interacting processes and pathways. 
Thus, a dose-response curve for lithium is likely to be highly nonlinear and not always monotonic.  
There are just a few well-established markers for optimum concentrations. For a patient 
with a reliable diagnosis of bipolar disorder a common target for optimality would be blood 
concentration of 0.8-1 mM.  Significantly higher concentrations will result in acute toxicity, while 
significantly lower will result in loss of effectiveness.  However, this level has some side effects 
when sustained for years or decades, namely an increased risk of kidney damage and lowered 
thyroid activity. 
At the other end of the dosage scale, epidemiological evidence is compelling that 
geographical variations in concentration of lithium in the drinking water are correlated with a 
variety of health and wellness markers. 
Another important marker is provided by a study showing that over a four-year period a 
lithium level of .25-.4 mM of lithium (1/4 to 1/2 of the bipolar therapeutic dose) did not incur any 
renal damage66. This study suggests that clinical studies exploring low to medium-dose lithium 
could be undertaken with relatively minimal concerns for side effects. 
One possible piece of low-hanging fruit for a clinical trial would be low- to medium-dose 
lithium for men undergoing active surveillance (AS) for advance of prostate cancer.  From studies 
of AS outcomes, a large fraction of patients on AS ultimately require invasive treatment, as 
reviewed by Dall’Era et al67. When this need arises it typically comes after only a few years.  Thus, 
a trial of lithium in this context would produce significant results in a short time and would be 
relatively inexpensive. One of us (EJ) conducted an informal one-person trial on himself after 
being diagnosed with prostate cancer in 2014, ingesting lithium supplements sufficient to bring his 
blood lithium to .3-.4mM while undergoing AS by Memorial Sloan Kettering Cancer Center.  
MSK did not prescribe the lithium but agreed to include lithium level measurement in periodic 
blood tests.) In October 2017 EJ was told that there was no longer a need for AS. One case, 
important as it is to EJ, does not have statistical significance. We need clinical trials with 
significant numbers of people. 
We will be happy to collaborate on further specific pathway or network analysis relevant 
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Abstract 
Association studies have been successful at identifying genomic regions associated with 
important traits, but routinely employ models that only consider the additive contribution of an 
individual marker. Because quantitative trait variability typically arises from multiple additive and 
non-additive sources, utilization of statistical approaches that include main and two-way 
interaction marker effects of several loci in one model could lead to unprecedented characterization 
of these sources. Here we examine the ability of one such approach, called the Stepwise Procedure 
for constructing an Additive and Epistatic Multi-Locus model (SPAEML), to detect additive and 
epistatic signals simulated using maize and human marker data.  Our results revealed that 
SPAEML was capable of detecting quantitative trait nucleotides (QTNs) at sample sizes as low as 
n = 300 and consistently specifying signals as additive and epistatic for larger sizes. Sample size 
and minor allele frequency had a major influence on SPAEML’s ability to distinguish between 
additive and epistatic signals, while the number of markers tested did not. We conclude that 
SPAEML is a useful approach for providing further elucidation of the additive and epistatic 
sources contributing to trait variability when applied to a small subset of genome-wide markers 
located within specific genomic regions identified using a priori analyses.    






The ability to identify genomic regions containing gene(s) associated with quantitative 
phenotypes has great potential for elucidating the genetic architecture of traits (e.g. number of 
genes, their effect sizes, additive vs. non-additive sources), as well as identifying targets for 
marker-assisted selection in plants and animals and therapy in humans. One analysis that seeks to 
identify such regions is the genome-wide association study (GWAS), in which statistical analyses 
are conducted on a set of markers spanning a species’ entire genome to determine which marker 
subsets exhibit the strongest associations with a trait of interest (reviewed in Lipka et al, 2015)1. 
In general, statistically significant marker-trait associations suggest that functional variants for the 
trait under study are located in the surrounding genomic region. To date, GWAS have been able 
to identify genes associated with many important traits, e.g. predisposition to breast cancer and 
diabetes in humans 2,3, and provitamin A levels in maize4. At present, GWAS is one of the most 
actively researched and applied methods for investigating the genomic underpinnings of 
Alzheimer’s disease5, coronary heart disease6, Parkinson’s disease7, carotenoid biosynthesis in 
maize8, and disease resistance in cattle9, among others. Thus, the ability of GWAS to identify 
specific genomic regions associated with traits critical for human health and agronomic 
performance has been demonstrated, and continued refinement of the statistical approaches in 
GWAS could make this analysis even more relevant for quantitative genetics research and its 
applications. 
The simplest and most widely used analytical approach for GWAS is to perform a separate 
statistical test for association between each marker and the evaluated trait. For example, a GWAS 
conducted to identify loci associated with the presence/absence of a disease in humans might 
perform either a Pearson’s chi-square test or conduct logistic regression separately for every 
marker in a genome-wide marker set10,11. Similarly, a GWAS conducted for a quantitative 
agronomic trait in a given crop12 might use the unified mixed linear model (MLM)13 that includes 
both fixed effect covariates to account for false positives arising from population structure and 
random effect covariates to account for those arising from familial relatedness.  
Although testing each marker individually has been effective in identifying statistically 
significant marker-trait associations in a wide variety of species and traits, it suffers from two 
major biological drawbacks. First, the consideration of only one marker at a time makes it 
impossible to quantify the simultaneous contributions of multiple functional variants located 
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throughout the genome in one statistical model. Second, these single-marker statistical tests 
typically do not consider the contributions of certain types of non-additive sources of variation, 
such as epistasis. Improvements to the typical statistical models used for GWAS could lead to 
more effective models. 
Both theoretical14,15 and empirical16,17,18 quantitative genetics research suggest that 
quantitative trait variation is under the control of multiple functional variants. Thus, statistical 
approaches need to complement this by including multiple markers in one model. Stepwise model 
selection is one of the simplest approaches for simultaneously estimating the additive effects of 
multiple loci. Here the additive effect of every marker throughout the genome is considered for 
inclusion as an explanatory variable in an optimal model. An extremely useful application of this 
approach is the multi-locus mixed-model (MLMM)19. In the MLMM, stepwise model selection is 
conducted on a given set of markers and false positives are controlled for by including the same 
fixed and random effects covariates as those used in the unified MLM13. An important advantage 
of the MLMM and similar approaches over single marker analyses is their capability to 
substantially lower false positive detection rates of marker/trait associations19. The MLMM has 
been shown to be useful for GWAS in crop diversity panels, especially as an extra step to further 
elucidate the signals already identified by an initial genome-wide scan using the unified MLM4,20,21  
Another application of stepwise model selection in GWAS is found in the US maize nested 
association mapping (NAM) panel22,23,24, where it is called joint linkage (JL) analysis. The maize 
NAM panel consists of 25 recombinant inbred line (RIL) families that share a common parent. To 
account for the family structure of the NAM panel, JL analysis starts with a baseline model 
containing the trait of interest as the response variable and the families as a fixed effect. Stepwise 
model selection is then conducted, where the nested additive effect of each marker within each 
family is considered for inclusion into an optimal JL analysis model. The use of JL analysis on the 
US maize NAM population data has proven fruitful for dissecting the genomic sources of many 
quantitative traits, including flowering time22, inflorescence25 and leaf blight26. Although the 
number of markers considered in these studies is orders of magnitude smaller than those currently 
available from high-throughput genotypic and/or phenotypic data, it is encouraging that this 
statistical approach successfully provided insight into the genetic architecture of those traits. To 
facilitate its broader adoption in GWAS, JL analysis has been made available in the graphical user 
interface (GUI) of TASSEL527, a publicly available Java package.  
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Non-additive sources of genetic variation are hypothesized to contribute to the 
discrepancies reported between the observed signals identified in GWAS and what is theoretically 
expected given the heritability of the trait under study28. Epistasis, generally defined as the 
interaction effect between alleles at two or more genomic loci29, is one such non-additive source. 
The direct quantification of epistatic effects by inclusion into multi-locus statistical models could 
improve our understanding of the genomic architecture of traits. A number of statistical approaches 
have been described for this purpose (e.g. Cordell, 2002; Haley and Knott, 1992; Jannink and 
Jansen, 2001; Karkkainen et al, 2015)30,31,32,33 and computationally efficient software has been 
developed. In particular, FastEpistasis34, Glide35, EpiGPU36, Boost37, multiEpistSearch38  and 
EPIQ39 explicitly search for pairwise epistasis among a set of markers provided by the user. 
However, none of the statistical models used in these packages can incorporate contributions from 
multiple pairs or higher-order combinations of interacting loci. This is a significant drawback, as 
a substantial proportion of non-additive variation could be attributable to multiple sets of 
epistatically interacting loci. In this manuscript we evaluate the Stepwise Procedure for 
constructing an Additive and Epistatic Multi-Locus model (SPAEML), which could potentially 
remedy that drawback. 
We extended the TASSEL5 code for JL analysis to implement SPAEML and tested its 
ability to detect additive and epistatic QTNs as a function of sample size and number of markers. 
To achieve this, we used genomic data from 2,648 individuals from the North Central Regional 
Plant Introduction Station (NCRPIS) maize diversity panel40 and from an Alzheimer’s disease 
(AD) case-control cohort consisting of 2,099 human subjects41 to simulate traits with different 
heritabilities and QTN effect sizes. Since these were not nested association mapping populations, 
the effect of nesting was not enabled in any of our analyses. We compared SPAEML to two other 
methods. The first, JL analysis, constructs a multi-locus model for additive marker effects and 
therefore will always misspecify any epistatic markers included in the model as additive. In 
contrast, FastEpistasis focuses on the interaction effect of one marker pair at a time; thus any 
additive signals identified by this approach will be misspecified as epistatic. Our hypothesis was 
that SPAEML can detect and correctly specify both types of markers.  
Materials and Methods 
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Stepwise procedure for constructing an additive and epistatic multi-locus model 
(SPAEML) 
The statistical approach implemented for SPAEML is similar to those previously described 
(e.g.  Bogdan et al, 2004; Yu et al, 2008)24,42. Briefly, this procedure involves identifying the 
optimal version of the multi-locus linear model that combines additive and epistatic effects: 
𝑌𝑖 = 𝜇 + ∑ 𝛽𝑗𝑥𝑖𝑗 +𝑗∈𝐼 ∑ 𝛾𝑢𝑣𝑥𝑖𝑢𝑥𝑖𝑣 +(𝑢,𝑣)∈𝑈 𝜀𝑖       (i) 
for a data set consisting of n individuals and m markers denoted by 𝑥1, … , 𝑥𝑚. In this model, 
𝑌𝑖 is the observed trait value of the i
th individual (e.g., human subject or plant accession); 𝜇 is the 
grand mean; 𝛽𝑗  is the additive effect of the j
th marker; 𝛾𝑢𝑣 is the two-way epistatic term between 
the uth and the vth marker; I is a subset of the m markers with additive effects included in the 
model; U is another subset of markers with two-way epistatic effects included in the model; 𝑥𝑖𝑗, 
𝑥𝑖𝑢, and 𝑥𝑖𝑣 denote the observed genotypes coded additively at the j
th,  uth, and vth marker loci 
respectively for the ith individual; and 𝜀𝑖 represents a normally distributed random error term. A 
stepwise model selection procedure is used to determine the optimal sets of markers belonging to 






• Genotypic and phenotypic data 
To evaluate the statistical performance of SPAEML we conducted two independent 
simulation studies: one using genotypic data from a maize diversity panel, and one using genotypic 
data from a human case-control study. The maize data were from the NCRPIS maize diversity 
panel40, consisting of a collection of 2,815 diverse maize inbred lines from throughout the world. 
We focused on a subset of 2,648 individuals genotyped for 681,257 single nucleotide 
polymorphisms (SNPs) using genotyping-by-sequencing (GBS)43. These data are publicly 
available at: http://cbsusrv04.tc.cornell.edu/users/panzea/filegateway.aspx?category=Genotypes. 
The second dataset is from the Mayo Clinic late-onset Alzheimer’s disease GWAS, which consists 
of 844 Alzheimer’s disease (AD) cases and 1,255 controls41. All 2,099 of these individuals were 
genotyped using 213,528 SNPs located within +/- 100 kb of 24,526 genes whose transcript levels 
were measured in Zou et al (2012)41. These data are available at:  
https://www.synapse.org/#!Synapse:syn2910256.  
Within each species, we constructed multiple test datasets varying in sample size and 
number of markers. All test datasets consisted of either the full set of individuals (n = Max; i.e. 
2,648 maize or 2,099 human individuals), or the same random subset of n = 300 individuals in 
each species. Similarly, the test datasets included either a random subset of m = 15,000 SNPs or a 
random subset of m = 5,000 SNPs. For both species, all SNPs in the 5,000-marker set were also 
included in the 15,000-marker set.  
Traits were simulated as previously described in scheme 2 of (Zhang et al, 2010)44 for each 
of the above data subsets. First, additive and/or epistatic quantitative trait nucleotides (QTN) were 
randomly selected from a subset of markers that were present in both the 5,000- and 15,000-marker 
subsets from each species. For consistency across all simulation settings, the range of possible 
QTN effect sizes was bounded by 0 and 1. A total of five simulation settings were used (Table 
5.1), each with differing numbers of additive and epistatic QTN, their effect sizes, and the broad-
sense heritability values (𝐻2). To empirically evaluate the false positive detection rate of SPAEML 
in the absence of genomic signals, the traits simulated in the first setting had zero QTN and 𝐻2 =
0. The genomic sources of variation underlying the traits in the next setting consisted of four 
markers that were randomly selected to be additive QTN and four additional marker pairs that 
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were randomly selected to be epistatic QTN. The additive and epistatic QTN both followed a 
geometric series; that is, the QTN with the 𝑗𝑡ℎ largest effect size was 0.95𝑗. Since the purpose of 
this setting was to evaluate the ability of SPAEML to identify signals for a trait with an ideal 
genetic architecture, the heritability was set at 𝐻2 = 0.99. To assess whether SPAEML can 
distinguish between additive and epistatic signals, the next setting consisted of two simulated QTN 
containing both nonzero additive and nonzero epistatic effects. Thus, the additive effects of these 
two QTN were 0.90 and 0.81, and the epistatic effect of these two QTN was 0.9. All traits 
simulated at this setting had a broad-sense heritability of 𝐻2 = 0.95. 
The next simulation setting strove to emulate the genetic architecture of a trait one might 
expect to find in a crop species. Thus, traits simulated in this setting were loosely based on the 
contrasting genetic architecture of inflorescence traits between maize and teosinte16,45. The genetic 
underpinnings of these simulated traits consisted of one two-way epistatic QTN of effect size 0.90, 
26 additive QTN with the effect size of the 𝑗𝑡ℎ QTN set to 0.45j, and a broad-sense heritability of 
𝐻2 = 0.92. In a similar vein, the next setting was based on the genetic architecture of Alzheimer’s 
disease in humans46,47,48. For this setting, a large-effect additive QTN with effect size of 0.90 and 
a geometric series of 19 additive QTN with the effect size of the 𝑗𝑡ℎQTN set to 0.40𝑗were 
simulated. In addition, a two-way epistatic QTN with effect size 0.70 was simulated. To imitate 
the contributions of the APOE gene to Alzheimer’s disease46, one of the two loci contributing to 
this epistatic QTN was the same as the large-effect additive QTN with effect size of 0.90. 
Consistent with the literature48, all traits simulated in this setting had a broad-sense heritability of 
𝐻2= 0.34.  
A total of 100 traits were simulated for each setting, species, and sample size. For a given 
simulated trait and sample size, the cumulative additive and epistatic QTN effects were calculated 
across all individuals. The variance of these cumulative effects comprised the genetic variance 
component of the trait. Finally, for a given 𝐻2, we simulated a normal random variable with mean 
0 and variance 𝜎𝑟
2, where 𝜎𝑟
2 is determined from 𝐻2. That is, if we let 𝜎𝑔
2 denote the genetic 
variance component of the trait, then the variance of this normal random variable is calculated by 







2         (ii) 
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Thus, any simulated trait value from a particular individual equals the sum of the 
cumulative QTN effects and the observed value of the aforementioned normal random variable. 
For the first setting, with zero QTN and 𝐻2 = 0, this normal random variable was simulated with 
a variance of 𝜎𝑟
2 = 1. 
 
• Statistical models fitted to each trait at each setting 
For each trait that was generated in the simulation study, SPAEML, JL analysis, and 
FastEpistasis were conducted to identify markers exhibiting peak associations with additive and 
epistatic QTN. For each of the five simulation settings, sample sizes, species, and number of 
markers, two separate permutation procedures (described in Churchill and Doerge, 1994)49 were 
conducted 100 times to empirically determine the inclusion and exclusion P-value thresholds that 
control the Type I error rate at 0.05: once for SPAEML and once for JL anlaysis. We conducted 
SPAEML using a Java package derived from the original TASSEL5 suite, but with the added 
ability to include epistasis (https://bitbucket.org/wdmetcalf/tassel-5-threaded-model-fitter). 
Additionally, the built-in stepwise model selection procedure from TASSEL was used to conduct 
the stepwise model selection procedure that only considered additive marker effects, a procedure 
which we refer to as joint linkage (JL) analysis. The FastEpistasis package was obtained from 
http://www.vital-it.ch/software/FastEpistasis, and Bonferroni correction was applied to control for 
multiple testing. FastEpistasis only tests one pair of markers at a time and constructs a model that 
includes additive effects for each marker and a two-way interaction term that models their epistatic 
effect. 
• Criteria used to quantify the detection of QTNs 
For a trait simulated under a given sample size, marker number, species, and setting, a QTN 
was said to have been detected by one of the three statistical approaches if either a marker 
contributing to the QTN itself or at least one marker located within a surrounding +/- 250 kb 
window was i.) included as a main (additive) effect in SPAEML or JL analysis, ii.) included as 
part of a two-way interaction (epistatic) effect by SPAEML, or iii.) included as part of a two-way 
interaction effect with a P-value less than or equal to the Bonferroni-adjusted 𝛼 = 0.05 threshold 
when analyzed in FastEpistasis. Thus, an approach’s (i.e., SPAEML, JL analysis, or FastEpistasis) 
detection rate of a QTN was defined to be the proportion of the corresponding 100 simulated traits 
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in which a QTN was detected. A similar metric specific to SPAEML, the specification rate of a 
QTN, was defined as the proportion of 100 traits where an additive QTN was correctly identified 
by SPAEML as additive, and both loci contributing to an epistatic QTN were correctly identified 
by SPAEML as epistatic. A window size of +/- 250 kb has been previously used in maize diversity 
panels to designate local regions of genomic proximity in maize50,51. To enable a side-by-side 
comparison of results between the two species, the same +/- 250 kb window size was used in the 
human data. 
A false positive (FP) detection was said to occur for i.) each main effect detected by 
SPAEML or JL analysis corresponding to a marker located outside of the +/-250 kb windows 
surrounding all QTN and ii.) each two-way interaction effect detected in SPAEML where both 
corresponding markers were located outside of the +/- 250 kb windows surrounding all QTN, or 
when iii.) a statistically significant association outside of these windows was identified by 
FastEpistasis. Hence the FP rate of a given approach was defined to be the proportion of 100 traits 
simulated at a given sample size, marker number, species, and setting with at least one FP.  
Results 
We conducted a simulation study to explore the impact of sample size and number of 
markers on the ability of SPAEML to identify additive and epistatic QTN. To enable a thorough 
investigation, traits with different genetic architectures ranging in complexity were simulated 
using genotypic data from a maize diversity panel and then again with genotypic data from a 
human case-control cohort (Table 5.1).  Figure 5.1 shows that the distributions of minor allele 
frequencies (MAFs) of the 15,000 markers considered in both species are vastly different. While 
the majority of the 15,000 SNPs in the maize diversity panel have MAFs below 0.1, the majority 
of the 15,000 SNPs in the human case-control study have MAFs that are greater than 0.1. Within 
both data sets, the MAFs of the markers randomly selected to be QTNs span the entire range of 
observed MAFs. These patterns enabled us to observe the way the collective distribution of allele 
frequencies in a marker set influenced the performance of SPAEML. 
Observed false positive rates across the five genetic architectures 
The purpose of simulating traits under the “Null” setting was to evaluate the effectiveness 
of the premutation procedure (used for SPAEML and JL analysis) and the Bonferroni procedure 
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(used for FastEpistasis results) to control the type I error rate at 𝛼 = 0.05.  The observed empirical 
FP rates across species, number of markers, and sample sizes suggest that these procedures are 
controlling for type I errors reasonably well, with SPAEML having empirical FP rates that are 
most consistently close to 𝛼 = 0.05 (Figure 5.2). The FP rates are generally higher for simulation 
settings other than “Null,” especially for the traits simulated under the “Ideal” genetic architecture 
(𝐻2 = 0.99, all QTNs have large effect; Table 5.1) in maize (Supplementary Figure 5.1). These 
results are not surprising because it is theoretically possible for all three approaches to identify 
markers that are in linkage disequilibrium (LD) with the simulated QTN. FastEpistasis, which tests 
the epistatic effect of one pair of loci at a time, tended to yield higher FP rates than the other two 
stepwise approaches, while SPAEML tended to have low FP rates at the maximum sample sizes 
in both datasets (Supplementary Figure 5.1).  
Accuracy of SPAEML at a limited sample size of n = 300 individuals 
The results from these simulation studies show that sample size has a substantially greater 
impact on QTN detection than the number of markers, underscoring the well-established 
importance of having sufficient sample sizes when conducting quantitative genetics analysis52. 
Nevertheless, to ascertain the limits of the ability of SPAEML to identify genomic signals, all five 
simulation settings were run with n = 300 individuals. One of the most detrimental impacts of 
small sample size on the accuracy of SPAEML appeared to be on the FP rate; substantially high 
FP rates from SPAEML were observed only at n = 300 (Supplementary Figure 5.1). In contrast, 
the FP rates for JL analysis and FastEpistasis were more consistent across sample sizes. At n = 
300, SPAEML detected QTN at rates vastly superior to those of FastEpistasis, but not as high as 
those of JL analysis (Figure 5.3a; Supplementary Figures 5.2-5.9). Finally, we observed that at n 
= 300, SPAEML is more likely to misspecify additive QTN as epistatic and identify only one locus 
contributing to an epistatic QTN (Figure 5.3b; Supplementary Figures 5.10-5.17). In contrast at n 
= max, SPAEML yielded i.) minimal FP rates, ii.) QTN detection rates that were comparable to 
JL analysis, iii.) greater capability to identify both loci underlying epistatic QTN, and iv.) the 
capacity to distinguish between additive and epistatic signals in traits simulated in the human 
dataset. In light of this contrast and the negligible impact of the number of tested markers on the 
simulation results, the remaining sections present findings based on n = max individuals and m = 




Distinguishing between additive and epistatic signals at the same locus 
Among the three approaches that were evaluated, only the output of SPAEML provide 
results for both additive and epistatic terms fitted to one model. To characterize the ability of 
SPAEML to distinguish between additive and epistatic signals, both of the QTNs considered in 
the “Additive vs. Epistatic” setting harbored non-zero additive and epistatic effects. At this setting, 
we observed contrasting results between the two species. In maize, SPAEML classified the signals 
at these QTNs as epistatic 100% of the time, suggesting that SPAEML was unable to distinguish 
between these additive and epistatic effects (Supplementary Figures 5.12-5.13). Contrastingly, 
SPAEML identified the additive and epistatic signals underlying both QTN simulated in the human 
dataset for all simulated traits. Similar results were obtained for the Alzheimer’s disease-like 
(“AD-like”) setting, where the large-effect additive QTN also include a substantially large epistatic 
signal (Supplementary Figures 5.16-5.17).  
 
Accuracy in more complex genetic architectures 
We compared the accuracy of the three approaches in simulation settings 4 and 5, which 
approximate the polygenic underpinnings of maize inflorescence (“Inflorescence-like” in Table 
5.1) and Alzheimer’s disease (“AD-like”). Two important characteristics distinguish these two 
settings. First, “Inflorescence-like” was highly heritable (𝐻2 = 0.92) while “AD-like” was not (𝐻2 
= 0.34). Secondly, the effect size of the epistatic QTN was substantially higher relative to those of 
the additive QTN in the “Inflorescence-like” setting, whereas the strength of the epistatic QTN in 
the “AD-like” setting was not.  
The detection rate for additive QTN improved as a function of the effect size for both JL 
and SPAEML, with roughly comparable accuracy between the two approaches (Figure 5.4A). In 
the human dataset, SPAEML provided the added advantage of always correctly identifying both 
loci contributing to the epistatic QTN, and correctly specifying additive QTNs as a function of 
their effect size (Figure 5.4A and Supplementary Figures 5.16-5.17). This latter result intuitively 
makes sense: the stronger the QTN effect, the more likely it is to be distinguished from a non-
additive signal. Among the corresponding traits simulated with maize data, SPAEML was at most 
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capable of detecting one out of two loci contributing to an epistatic QTN, and all additive QTNs 
were misspecified as epistatic (Figure 5.4B). We hypothesize that the generally lower MAF 
observed in the markers from the maize dataset provided weaker statistical support for each of the 
simulated QTN, resulting in the observed misspecification. 
Discussion 
Statistical approaches that consider the additive and epistatic contributions of multiple 
genomic loci could enable unprecedented quantification of the genetic architecture of 
agronomically important and human health-related quantitative traits. Using genotypic data from 
a maize diversity panel and a case-control study of Alzheimer’s disease in humans, we conducted 
a simulation study to determine the accuracy and limits of applicability of SPAEML. Specifically, 
we assessed the impact of sample size, number of markers, MAF, and the genetic architecture 
underlying a given trait on the ability of SPAEML to detect and correctly specify additive and 
epistatic QTN. Our results suggest that sample size has greater influence on the performance of 
SPAEML than the number of markers, in all considered cases. Additionally, the capability of 
SPAEML to distinguish between additive and epistatic QTN was much greater when traits were 
simulated in the human data set, possibly due to the generally higher values of marker MAFs. At 
the maximum evaluated sample sizes, the detection rate of SPAEML was comparable to JL 
analysis, and unequivocally superior to that of FastEpistasis. 
Our study builds upon previous work31,32,33,53 that explicitly assesses the ability of 
stepwise-based or similar approaches to identify and distinguish between additive and epistatic 
genomic signals. Novel state-of-the-art computational approaches54 and inexpensive genotyping 
protocols43,55 are resulting in extremely large amounts of genotypic and phenotypic data. Larger 
sample sizes facilitate improved accuracy of analyses. However, exhaustive searches for multiple 
sets of epistatically interacting loci on a genome-wide scale in large datasets faces a difficult 
multiple-testing problem33. Stepwise model selection and related approaches have been successful 
in circumventing this problem in the past25,56,57 by considering a relatively small number of total 
markers in their analyses; this past success drove us to investigate SPAEML. 
Based on our results, we expect SPAEML will be particularly useful for quantifying 
additive and epistatic marker-trait associations in specific genomic regions that have been 
identified in a priori biological or statistical analyses. This will result in the analysis of a smaller 
 
 91 
set of markers, thus yielding a smaller search space for optimal models and enabling researchers 
to capitalize on the accuracy of SPAEML that we demonstrate here. Our exploration of the factors 
that influence the accuracy of SPAEML is not exhaustive, but is sufficient to complement so-called 
“search space reduction” efforts58,59 by providing a rough assessment of the number of markers to 
target within the genomic regions identified in a priori analyses.  
Effect of sample size 
Our study confirmed the common expectation that sample size positively affects the 
accuracy of SPAEML. We also demonstrated that SPAEML is capable of true positive detection 
and even correct specification of additive and epistatic QTN at the smaller sample size that we 
explored (n = 300). However, the accuracy improves dramatically at larger sample sizes. Although 
this result is unsurprising, direct quantification of SPAEML’s ability to identify additive and 
epistatic QTN at different sample sizes is informative, as it is useful to know how a model will 
behave on a smaller dataset when desired sample sizes are unavailable. Our results show that even 
in those cases SPAEML will find many significant SNPs and epistatic pairs, although they may be 
misspecified in the final model. 
Effect of the marker set size 
In contrast to the substantial impact of sample size on the accuracy of SPAEML, we 
observed similar true and false positive rates at the two marker sizes that were tested. From a 
statistical perspective, these results suggest that for these simulated data, the conservativeness of 
the multiple testing problem is similar for both 5,000 and 15,000 markers. Thus, the larger marker 
set does not decrease the accuracy of SPAEML. This is important, as our marker sets are orders of 
magnitude smaller than those currently available on a genome-wide scale in heavily researched 
species. We hope the usefulness of SPAEML holds for larger sets, although direct extrapolation is 
not recommended. We believe this method is best used on a set of markers that has been whittled 
down by using prior biological information, such as linkage disequilibrium analysis, hypothetical 
relations between markers and cellular pathways, or other preliminary analyses that remove 
markers that are least likely to contribute to the final model function. This will bring the problem 
into the setting of optimal performance for SPAEML, and also reduce the computational burden 
from testing both additive and epistatic effects, which grows binomially with the marker set size. 
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Effect of the minor allele frequency 
We found SPAEML to be much more capable of distinguishing between additive and 
epistatic signals for traits simulated in the human dataset, despite that the same number of markers, 
similar number of individuals, and the same simulated genetic architectures were evaluated in the 
maize and human datasets. We propose two distinct but not mutually exclusive hypotheses to 
explain these results. First, differences between the underlying characteristics of the maize and 
human genomes could result in LD-related properties being more favorable for SPAEML to work 
optimally in the human dataset. The second hypothesis is that the differences in accuracy are a 
downstream ramification of the difference in MAF distribution across the two datasets (Figure 
5.1), potentially explained by the procedures for data collection. The maize dataset is a diversity 
panel, meaning that it consists of a wide variety of genetically diverse species40. Thus rare variants 
are prominent, and consequently SNPs with low MAFs are observed. Although rare variants are 
undoubtedly also present in the human genome, recent research suggests that the humans tend to 
be far less genetically diverse than plants, having gone through multiple rounds of purifying 
selection during inter-continental migrations in human evolution60,61. Combined with the fact that 
the human data we analyzed were from a case-control study, low MAFs are less prominent. In any 
case, the differences in SPAEML accuracy suggest that both the genomic characteristics of a 
species and the distribution of MAFs among the tested markers could exhibit a critical impact on 
the results. 
Conclusions and next steps 
To ensure that the most appropriate biological conclusions are made by breeding, medical, 
and quantitative genetics research communities, it is imperative that statistical models which 
approximate the genetic architecture of traits are accurate. By design, both JL analysis and 
FastEpistasis oversimplify the intricate patterns of main effects and multifaceted interactions 
between loci contributing to phenotypic variability. While JL is designed to only consider additive 
effects in a multi-locus model, FastEpistasis is designed to only test for epistasis, one pair of 
markers at a time. In contrast, we demonstrate that SPAEML is a sensitive and accurate approach 
capable of identifying and distinguishing between additive and epistatic genomic signals, at least 
for datasets of several thousand samples and markers. We suggest that SPAEML, which conducts 
model selection for all possible main effects and two-way interaction effects of a set of markers, 
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is best used for constructing an accurate model on a limited set of markers identified through an a 
priori analysis, once the least-contributing markers have already been eliminated. To reduce the 
inherent computational burden with running SPAEML, we are currently working to migrate the 
Java code for SPAEML into Scala for a more scalable deployment on Spark. This will enable 
massive parallelization of the procedure. In the meantime, the Java program that conducts 
SPAEML is already available to the public free of charge.  
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TITLES AND LEGENDS TO FIGURES 
 
Figure 5.1. Distribution of the minor allele frequencies (MAFs) of the evaluated single nucleotide 
polymorphisms (SNPs). Box plots depicting the MAFs (Y-axis) of the 15,000 SNPs that were tested in the 
human dataset and the 15,000 SNPs that were tested in the maize dataset (X -axis).  The MAFs of all SNPs 
that were randomly selected to be quantitative trait nucleotides (QTNs) for the simulation studies are denoted 
by purple dots. These box plots illustrate that the MAFs of the SNPs in the maize dataset tend to be lower 





Figure 5.2.  Comparison of false positive rates for the three approaches evaluated in “Null” 
setting where no quantitative trait nucleotides (QTNs) were simulated. The rate of false positive detection, 
defined as a SNP located outside of +/- 250 kb of any of the QTNs, for joint linkage (JL) analysis, the stepwise 
procedure for constructing an additive and epistatic multi-locus model (SPAEML), and FastEpistasis are 
plotted on the Y-axis of each graph. Starting from the left, the first two graphs show the results for the traits 
simulated in the human data, while the last two columns show the results for the maize simulated data.  The 
graphs with the title “5k” show the results when 5,000 markers were tested, and the graphs with the title “15k” 
show the results when 15,000 markers were tested. The X-axis of each graph show the sample sizes that were 
tested, with max indicating the maximum sample size of each dataset (2,648 in the maize dataset and 2,099 in 





Figure 5.3.  Detection (A) and specification (B) rates of simulated quantitative trait nucleotides 
(QTNs) for the three approaches evaluated in the “Ideal” genetic architecture with setting with four 
large-effect additive QTN and four large-effect epistatic QTN and heritability equal to 0.99 (A). The 
detection rates of the additive QTNs, defined as the proportion of SNPs located within +/ - 250 kb of any of 
the simulated QTN detected using joint linkage (JL) analysis (red bar), the stepwise procedure for constructing 
an additive and epistatic multi-locus model (SPAEML; green bar), and FastEpistasis (blue bar) are plotted on 
the Y-axis of each graph. The first two rows (shaded pale yellow) show results for the simulated additive 
QTN, while the bottom two rows (shaded pale purple) show results for the simulated epistatic QTN. The first 
and third rows show results for the simulations conducted in the human dataset, while the second and fourth 
rows show results for the simulations conducted in the maize dataset. The X-axis on each graph depict the 
effect sizes of the QTN.  The left column shows results for n = 300 individuals and m = 15,000 markers, while 
the right column shows results for n = max individuals (i.e., n = 2,099 in humans and n = 2,648 in maize) and 
m = 5,000 markers.  Both JL and SPAEML are able to detect the additive and epistatic effects, while 
FastEpistasis failed to detect all the additive effects and most of the epistatic effects. (B) Specification rates 
of SPAEML, defined as the proportion of times that a detected additive QTN was correctly specified in the 
SPAEML model as additive, misspecified as epistatic (first two rows); or the proportion of times for a detected 
epistatic QTN that it was misspecified as additive, only one locus contributing to the QTN was detected, or 
both loci contributing to the QTN (bottom two rows). These proportions are depicted on the Y -axis of each 
graph. The X-axes of each graph, and how they are subdivided into rows and columns, are the same as in (A). 





Figure 5.4.  Detection (A) and specification (B) rates of simulated additive quantitative trait 
nucleotides (QTNs) for the three approaches evaluated in the two complex genetic architectures at a 
maximum number of individuals (n = 2,099 human subjects and n = 2,648 maize lines) and 15,000 
markers (A) The detection rates of the additive QTNs, defined as the proportion of SNPs located within +/- 
250 kb of any of the simulated QTNs detected using joint linkage (JL) analysis, the stepwise procedure for 
constructing an additive and epistatic multi -locus model (SPAEML), and FastEpistasis are plotted on the Y-
axis of each graph. The first row shows results for the simulations conducted in the human dataset, while the 
second row shows results for the simulations conducted in the maize dataset. The X-axis on each graph depict 
the effect sizes of the additive QTN.  The left column shows results for the inflorescence-like genetic 
architecture, while the right column shows results for the AD-like genetic architecture. Similar detection rates 
were observed across JL analysis and SPAEML, while FastEpistasis failed to detect all the additive effects. 
(B) Specification rates of SPAEML, defined as the proportion of times that a detected additive QTN was 
correctly specified in the SPAEML model as additive or misspecified as epistatic, are depicted on the Y -axis 
of each graph. The X-axes of each graph, and how they are subdivided into rows and columns, are the same 
as in (A). Correct specification of additive QTN occurs in the traits simulated using human data. 
“Inflorescence-like” = setting with 26 additive QTN, one epistatic QTN and heritability equal to 0.92; “AD -






Table 5.1. Description of the number of individuals, markers, and genetic architecture 
considered in the five tested simulation settings. 
 
aQTN, quantitative trait nucleotide 
bmax, denotes maximum sample size, that is 2,648 maize individuals and 2,099 human individuals 








No. of markers Heritability 
No. of additive 
QTNa 
(range of effect 
sizes) 
No. of epistatic 
QTN 
(range of effect 
sizes) 
1 = “Null” 300; maxb 5,000; 15,000 0 0 0 
2 = “Ideal” 300; max 5,000; 15,000 0.99 4 (0.81-0.95) 4 (0.81-0.95) 
3 = “Additive 
vs epistatic” 




300; max 5,000; 15,000 0.92 26 (9.63 x 10-10 – 
0.45) 
1 (0.90) 





CAPTER 6: Future Work - Search Space Reduction Approaches for GWAS 
Epistatic Model Selection 
 
The main focus of this thesis has been the development of methods to overcome multiple-
testing problem in complex biological scenarios. In chapters 1-3, I presented the application of 
non-parametric resampling method in gene ontology enrichment analysis. This method allows 
accurate estimation of p-values despite large number of tests performed on the dataset. However, 
this approach is not the end-all for every biological problem. In some situations, the number of 
possibilities to explore is so large that even the standard permutation procedure is not sufficient. 
In chapter 4, the permutation method is applied to evaluate a multi-locus model including both 
additive and epistatic approach for GWAS data of small size. While that worked well for smaller 
sample sizes, it was still very computationally intensive. The entire space of all possible models to 
evaluate grows as an exponential of binomials of the number of genomic markers. When 
evaluating more than ten thousand markers, brute-force approach becomes computationally 
infeasible. Therefore, one must first reduce the number of possible models to consider, a process 
known as "search space reduction". This is best accomplished by narrowing down the number of 
markers to those most likely to contribute to the phenotype. A number of tool packages and 
algorithms have been developed to address this problem, yet a consistent workflow is yet to be 
developed. In this chapter I provide an overview of the approaches that have been discussed in the 
literature, and suggest a way to synthesize a single, meaningful solution. Generally those 
approaches cluster into (1) machine learning or statistics algorithms to filter out SNPs that are least 
likely to carry a signal; (2) removal of SNPs by applying a-priori considerations not related to the 
biological problem in question, and (3) using prior knowledge about the biological problem being 
studied to narrow down on the SNPs most likely to be involved. 
Removal of SNPS least likely to contribute: LASSO, MDR, MAPIT 
It makes sense that among hundreds of thousands of SNPs present in each individual, only 
a small fraction actually contributes to the phenotype being studied. Thus, it is desirable to have 
some way to very quickly eliminate SNPs that are clearly unrelated to the problem and thus should 
not be taken into account when building the genotype-to-phenotype model.  
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One such method is LASSO: The Least-Absolute Shrinkage and Selection Operator1. It 
efficiently searches for the strongest effects while solving a constrained least-square problem, 
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LASSO effectively shrinks coefficients of insignificant terms to zero, and could be used to 
quickly pre-screen a large number of markers before proceeding with actual model construction. 
The Screen and Clean package2 is built on this principle that a set of SNPs was selected by LASSO 
and then fitted into a more precise model. Other examples of using LASSO for GWAS include 
Graphic-guided fused lasso (GFLASSO)3 and Adaptive Group LASSO4. GFLASSO combines 
LASSO with genetic regulatory network. In the regulatory network, the SNPs associated with two 
directly interacting genes would be "fused" by having an additional penalizing term, so that the 
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𝑟𝑚𝑙 is the correlation derived from the interaction network. 
Kim, et.al. (2009) applied GFLASSO method on both simulation study and a case study 
on asthma data set and demonstrated that GFLASSO has improved accuracy compared to regular 
LASSO3. Yang, et.al. (2010)4 developed the model by updating penalizing coefficient recursively 
(adaptive group LASSO, AGL) and applied it on rheumatoid arthritis data set from the Wellcome 
Trust Case Control Consortium (WTCCC)5. Yang, et.al. (2010)4 suggested that while the adaptive 
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group LASSO outperforms regular LASSO in detecting and specifying interactive pairs, it is still 
limited by the search space and therefore requires search space reduction with biological filters.  
By definition, LASSO would quickly converge to the strongest effects. While many 
epistatic effects do not have a strong additive effect, LASSO is a good tool to build an initial coarse 
model.  
Multifactor Dimensionality Reduction (MDR)6 is a method of processing SNPs such that 
their combinations are collectively replaced by a single list of predictors. MDR categorizes allele 
combinations into high/low risk groups by phenotype values followed by a data-mining procedure. 
First, data is partitioned into different sections and the program start with one section. For each 
combination of alleles, the ratio of diseased phenotype is calculated3. If the ratio is higher than a 
pre-set threshold, the combination is considered “high-risk”3. Otherwise, the combination would 
be “low-risk”3. Then, the grouping into high and low risk is modified and cross-validated by other 
data sections3. This works very well for case-control studies. Generalized versions of MDR7,8 also 
extend its application to quantitative traits. Family Multifactor Dimensionality Reduction (FAM-
MDR)9 includes familial correlations derived from theoretical model. All these approaches derived 
from MDR method effectively collapse allele combination into 1D vector. SNPHarvester10 is a 
package that combines MDR method and LASSO-like regression to identify interacting SNPs, 
which efficiently detect disease-associated SNPs. The authors for SNPHarvester points out that 
the package would perform better if guided by knowledge of biological knowledge to pre-select 
"Good" SNPs10. Similarly, prior knowledge of biological pathways, as implemented in Pathway 
Genetic Load (PGL)11. It generates weighed sum of important loci in the pathway associated with 
the phenotype and uses weighed sum instead of a vector of genotype values for regression. Instead 
of predicting which combination is most likely to contribute to the trait based only on statistics, 
PGL pre-selects alleles that are associated with pathways and combines them with a score. The 
scores would again replace the SNP combinations to be associated with the trait. Crawford, et.al. 
(2017) proposed PGL to evaluate SNPs affecting traumatic injury prognosis for sepsis and death 
by analyzing loci in the TLR4 signaling and response pathway14. 
Random Forests is a machine learning procedure especially suitable for categorical 
phenotypes. SNPs are partitioned so that combination of SNPs would lead to almost clear 
separation of phenotype categories. For example, Goldstein, et.al. (2010) applied random forest 
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on multiple sclerosis (MS) case-control dataset and obtained genes bolstered by previous study as 
well as new candidate genes12. However, Winham, et.al. (2012) has pointed out that the 
performance of random forest decreases as dimensionality increases and therefore might not be 
suitable for complex phenotypes13. 
MAPIT is a method that identifies variants that exhibit non-zero epistatic interactions with 
any other variant without the need to identify the specific marker combinations that drive the 
epistatic association14. Therefore, it is also a good candidate in pre-selecting candidates for 
epistatic pair for more detailed fitting later. MAPIT is designed to study quantitative trait with two-
way interaction, but the model is readily extensible to categorical trait and higher-order 
interactions. Since the marginal epistatic effect instead of explicit combination is evaluated, 
MAPIT can efficiently search candidate SNPs for interactions. However, MAPIT explicitly went 
through each SNP, which renders it less efficient than LASSO. 
Overall, LASSO might be a straightforward and efficient pre-filtering method to quickly 
build an additive model, if the potential model would be sparse. Other methods might be included 
later to further improve the pipeline to accommodate different data features. 
A-priori biological considerations: LD pruning 
Most organisms, especially complex multicellular eukaryotes, have chromosomal regions 
called "haplotype blocks" wherein groups of genetic variants are likely to be inherited together15. 
Replacing single SNPs with haplotyping blocks (or randomly choosing one SNP out of a set in 
one block) drastically reduces the total number of SNPs that participate in the model selection 
process. Linkage-Disequilibrium is a statistical approach to identify haplotype regions on 
chromosomes1. Software packages LINDEN16 and BEAM17 facilitate this process by analyzing 
high-LD regions. PASCAL18 and SKAT19 annotates SNPs onto genes that are in high-LD with 
them. After haplotyping SNPs, each haplotype group is considered as one variable in the model 
and represented by a randomly select SNP in the group. 
 
Using information from biological pathways and functions  
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In addition to haplotyping and PGL, SNP-pair search methods based on prior biological 
hypotheses have also been explored. For example, Reverse Pathway Genetic Approach starts with 
knowledge of pathways associated with a Mendelian disorder, identifies SNPs that are in epistasis 
with the genes of the pathway, and compares these SNPs with rare, major effect mutations involved 
in the pathway20. Ritchie (2011)21 has reviewed the potential of combining regulatory networks 
and pathways for filtering out SNPs that are likely to interact with each other. Liu et.al. (2012)22 
selects SNPs in disease-associated regulatory network and performs two-locus analysis to detect 
epistatic pairs. In group LASSO, an additional penalize term is included so that the coefficient for 
SNPs sharing an edge in regulatory network would shrink to zero at the same time. These methods 
involve the accuracy of pre-selecting the candidate SNPs but do not utilize the regulatory network 
data to expand the final model. Using similar methods, one could build an interaction matrix 
describing how likely the epistasis pair would form. To build the interaction matrix, several data 
source can be utilized: (1) sequencing data such as ChIP-Seq for direct transcription factor binding 
information23 and Hi-C for chromatin structure24, (2) networks derived from the sequencing data 
such as GTEx project25 and Juicebox toolkit24, (3) co-expression data from microarray 
experiments, (4) protein-protein interaction data from BioGRID26 and STRING27. Software like 
d2z28 and Jellyfish29 calculate the k-mer distribution in promoter region, which can be applied to 
evaluate similarity in the promoter regions and predict co-regulation. MatInspector also calculates 
promoter region similarity for co-regulation prediction but based on alignment instead of k-mer 
distribution.30 A study on Merino sheep pigmentation used MatInspector to construct regulatory 
network and used the network to predict epistatic pairs31. A recent algorithm called SPADIS 
further give more weights to SNP groups that are distantly connected in a regulatory network to 
ensure coverage over biologically meaningful pathways that might otherwise blurred by nearby 
high LD regions32. Hi-C data is included in the SPADIS method to consider physical distance of 
SNPs in a 3D structure24,32. (4) Exploration into evolutionary history of chromosome 
rearrangement might bring some insight into inter-chromosome epistasis.  
These biological toolkits and databases indicate the likelihood a SNP (group) would be 
interacting with another SNP (group). With these information, the candidate SNP to be added into 
the model would be ranked.  The step-wise procedure would then include and evaluate the 




Proposed workflow to synthesize the above methods into one automated 
solution 
 
Haplotyping using PASCAL or SKAT would be the first step. These packages not only 
group SNPs, but also associate them with genes. After this step, SNPs are grouped for reduced 
number of variable, and annotated to incorporate biological analysis. 
Then, a LASSO procedure is conducted to build an initial model. LASSO would quickly 
filter for the haplotypes with strongest effect as candidate.  
Meanwhile, multiple packages are applied in analyzing biological network depending on 
the input gene list size. If hundreds of genes are annotated, Packages like KnowEng33 and 
Magnum34 would incorporate multiple biological databases to predict candidate interactions. If 
SNPs of interest are collapsed near only a few genes, probably databases like co-expression35, or 
promoter region similarity analysis like D2z28 would indicate the most likely co-regulatory genes. 
Moreover, our script generating direct annotation to chromosome region, active CTCF binding 
sites, and Hi-C data using ANNOVAR36 would model the contact probability in chromatin regions. 
Then, a matrix of pairwise interaction probability is generated from all the analysis. 
In the SPAEML procedure, candidate SNPs are added into the model following the 
interaction probability stochastically. When significance is reached, search for model would stop. 
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In summary, the next stage of the work is to build a modeling pipeline integrating search 
space reduction method with SPAEML. SNPs are grouped in haplotype blocks and each block is 
replaced by single representative SNP. A coarse model is built by LASSO. To avoid exhaustive 
search, candidate SNP and pairs are prioritized with biological information and added into the 
model in a stochastic way. 
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